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In vivo gene replacement for the treatment of inherited pathologies is one of the 
most compelling concepts in modern medicine and recombinant adeno-
associated virus vectors (rAAV) offer nowadays a real promise for gene therapy of 
several diseases. Recombinant adeno-associated virus vectors definitely possess a 
large number of properties that render them suitable for clinical gene therapy, 
including being based upon a virus that is not related to any human known 
pathology and shows natural propensity to persist in human post mitotic cells in 
an episomic form. Given the molecular simplicity of AAV vector particles, all the 
determinants of permissivity to vector transduction appear to reside among the 
molecular features of the host cell. For this reason, the identification of the cellular 
proteins that regulate vector transduction is an essential requisite to improve in 
vivo transduction, expand the number of permissive tissues and achieve AAV-
mediated gene correction at a clinically applicable level.  
The aim of this PhD thesis was to study and understand the cellular mechanisms 
that regulate Adeno-associated virus transduction. This work was performed 
exploiting high throughput screening technologies. Taking advantage of genome-
wide siRNA libraries it was possible to identify some relevant cellular factors that 
mediate rAAV2 transduction. Differences in AAV transduction in HeLa cells were 
assessed using a recombinant ssAAV2 vector expressing the firefly Luciferase 
reporter gene. Analysis of the results obtained from this primary screening 
identified 1528 genes affecting transduction by AAV vectors by more than 4-fold 
(184 genes by more than 8-fold). Of these genes, 993 are inhibitors of AAV 
transduction, whereas 535 are required for efficient transduction by AAV vectors. 
The work described in this thesis is divided in two sections. The first part focuses 
on the characterization of the top-10 siRNAs identified in the screening that were 
able to increase rAAV transduction in HeLa cells from 19 up to 50 folds and 
therefore targeting factors inhibitory on rAAV transduction. This part of the 
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research highlights new mechanisms that describe the correlation between AAV 
infection and cellular checkpoint activation. The second part of the thesis focuses 
on the study of factors required for rAAV infection. In particular, we characterize 
the mechanism of action of Eri1, a 3’-exoribonuclease known to degrade 
endogenous miRNAs and histone mRNAs, on AAV transduction. We determined 
that Eri1 is essential for ssAAV but not scAAV transduction and that effect is 
specifically exerted by changing the AAV genome chromatin composition through 
the modulation of the cellular histone dosage. 
The findings described in this thesis may foster the development of druggable 
siRNA molecules or pharmacological strategies specifically aimed at improving 
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1. Introduction 
 
The development of suitable vectors for gene therapy has been a challenging goal 
over the past decade; the enormous potential of this approach has attracted the 
attention of an increasing number of researchers. To date, several classes of viral 
and non-viral vectors are being exploited as tools for delivering therapeutic 
genetic information into cells for the treatment of a wide variety of inherited 
disorders in clinical and pre-clinical trials (Figure 1.1). One of the most promising 
virus vectors being studied for human gene transfer is derived from the adeno-
associated virus (AAV), a single-stranded, non-pathogenic DNA virus that is 
ubiquitous in humans. Recombinant AAV (rAAV) vectors, indeed, represent today 
one of the most popular viral vector systems for gene transfer applications. The 
favourable characteristics of these vectors include broad tropism, simplicity of 
their genome devoided of any gene of viral origin, limited capacity to induce 
immune responses after in vivo administration, capacity to transduce postmitotic 
cells and to drive persistent, virtually life-long-lasting expression of the encoded 
genes. Due to these favorable characteristics, recombinant AAV (rAAV) vectors  
offer a valuable tool that permits in vivo phenotypic assessment of gene function 
and pre-clinical disease modeling in small and large size experimental animals. 
Recombinant AAVs have being developed for an ever-growing variety of 
therapeutic applications. Among the clinical successes obtained using rAAV there 
is gene therapy for the Leber's congenital amaurosis diseases, which is an inherited 
blinding disease caused by mutations in the RPE65 gene (Buch et al., 2008). The 
results of first clinical trials have been promising, showing an increase in vision and 
most importantly the lack of side effects in treated patients (Cideciyan et al., 2009). 
Currently, a clinical trial administering an AAV vector by intraocular administration 
for the expression of the RPE65 gene, has reached phase III (Simonelli et al., 2010). 
Moreover, an AAV1 vector coding for the lipoprotein lipase (LPL) for the treatment 
of patients with familial LPL deficiency, has been the first gene medicinal product 
approved for marketing in the Western world, authorized by the European 
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Commission in 2012 under the commercial name of Glybera (Salmon et al., 2014). 
Promising results using rAAV technology have been obtained also for the 
treatment of Duchenne muscular dystrophy (DMD) and Parkinson’s disease (PD). 
The first clinical gene therapy trial for DMD began in March 2006 (Rodino-Klapac et 
al., 2007). This was a Phase I study in which an AAV vector was used to deliver 
micro-dystrophin to the biceps of boys with DMD. Recently, two phase I clinical 
trials on PD were conducted at the University of California San Francisco (UCSF) 
and Jichi Medical University (JMU) to evaluate the safety and potential efficacy of 
AAV vector–mediated gene delivery of aromatic l-amino acid decarboxylase gene 
(AADC) to the bilateral putamen. Alleviation of motor symptoms associated with 
PD was observed in both trials (Christine et al., 2009) (Muramatsu et al., 2010). 
CERE-110 is another therapeutic based on adeno-associated virus technology to 
deliver nerve growth factor gene (NGF) into the brain of patiences with Alzheimers 
disease (AD). The study is evaluating whether CERE-110 (AAV-NGF) is a safe and 
effective treatment for AD. Approximately fifty people with AD are participating in 
this study; data from this phase II trial will be available in 2015 (Mandel, 2010). 
Hemophilia B is another attractive target disease for rAAV gene therapy 
applications but a potential complication of a gene-based treatment is the 
development of neutralizing antibodies (NAb) against the therapeutic transgene. 
There are now three ongoing trials based on AAV-mediated gene transfer in 




	   13 
 
Fig 1.1 : Vectors used in Gene Therapy clinical trial. Adapted from (Sheridan, 2011). 
 
1.1. Overview of Adeno-associated vectors  
 
1.1.1 Wild type AAV virus 
 
Adeno-associated viruses belongs to the family of parvoviridae that comprises 
viruses with a linear, single-stranded DNA genome of approximately 5 kb and a 
non-enveloped, icosaedrical capsid with a diameter of 18-30 nm (Siegl et al., 1985). 
These features make parvoviruses the smallest DNA viruses in nature. Within this 
group, the adeno-associated viruses are classified in the genus of the 
Dependovirus (Lat. dependere: to depend), because they require exogenous 
factors for their replication, and this distinguishes them from autonomous 
parvoviruses. Dependoviruses and autonomous parvoviruses infect vertebrates. 
Another group of parvoviruses, the densoviruses, infects insects and replicates 
autonomously (Galev et al., 1989). AAV-2 was the first serotype discovered in 1965 
as contaminant of adenovirus preparations hence its name (Atchison et al., 1966). 
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for AAV-2 to replicate its genome and generate a productive viral infection (Casto 
et al., 1967). Later, studies demonstrated that other viruses such as herpesviruses, 
vaccinia and papillomaviruses were also able to boost AAV-2 replication, as well as 
several chemical, physical factors and carcinogenic compounds, genotoxic agents, 
UV or γ-irradiation (Johnson et al., 2011; McPherson et al., 1985) (Yakobson et al., 
1989). The wild type AAV viral genome contains two open reading frames (orf) and 
three promoters regulate the gene expression. From the first orf, four different 
RNAs are generated through alternative splicing; these code for the non structural 
Rep proteins (Figure 1.2). The two major forms of Rep (Rep78 and Rep68) bind 
specific sites within the inverted terminal repeats (ITRs), and are required for both 
viral DNA replication and site-specific integration (Senapathy et al., 1984). In 
addition, the AAV Rep proteins participate in the regulation of gene expression. In 
particular, Rep induces the up-regulation of the homologous AAV promoters in 
the presence of adenovirus infection, while it exerts an inhibitory effect when 
adenovirus is absent (Trempe and Carter, 1988). Rep is also able to down regulate 
other heterologous promoters, including viral and proto-oncogene promoters, 
suggesting a pleiotropic effect exerted by this protein on gene expression 
(Marcello et al., 2000). The mRNAs coding for Rep78 and its splicing variant Rep 68 
start at the p5 promoter and are 4.2 and 3.9 kb long respectively. The Rep52 
mRNAs and its splicing variant Rep40 start at promoter p19 and are 3.6 and 3.3 kb 
long respectively (Marcus et al., 1981). Proteins Rep78, 68, 52 and 40 consist of 621, 
537, 397 and 313 amino acids respectively (Mendelson et al., 1986). The CAP open 
reading frame, located at the 3’ end, codes for the three structural capsid proteins 
VP1, VP2 and VP3 that are transcribed from the p40 promoter and expressed at a 
ratio of 1:1:8 respectively (Kronenberg et al., 2001). Translation efficiency is 
regulated by the alternative splicing of the VP1 coding intron and by the use of an 
unusual initiation codon (ACG) for VP2 that leads to a 10-fold reduced translation 
of the protein in comparison to the AUG initiation codon of VP3 (Becerra et al., 
1988). AAV capsid proteins VP1, VP2 and VP3 use the same stop codon and have 
molecular weights of 90, 72 and 60 kDa respectively. The viral protein half life is 
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around 15 hours while its mRNAs are degraded within 4-6 hours (Senapathy and 
Carter, 1984). 
 
Figure 1.2 Genomic organization of the wtAAV genome. Rep transcripts are non-structural 
proteins – Rep40, Rep52, Rep68 and Rep78 – they are involved in gene regulation, viral DNA 
encapsidation and genome integration. VP1,2,3 are transcribed from the Cap gene, they are the 
structural proteins that compose the AAV capsid. 
 
 
Some authors recently showed that AAV encodes a protein required for capsid 
formation by means of a nested, alternative ORF in the Cap gene.  This protein, 
which was named assembly-activating protein (AAP), localizes in the host cell 
nucleolus, where AAV capsid particles assembling occurs. AAP targets newly 
synthesized capsid proteins to this organelle and, in addition, fulfills a function in 
the assembly reaction itself (Sonntag et al., 2010).  It is important to underline that 
the mechanism of assembly of AAV particles is not known in detail.  The whole 
coding region of AAV genome is flanked by two 145 bop ITRs (Figure 1.3), which 
show complementarity within the first 125 bp and form a T-shaped hairpin at both 
ends of the genome. This palindromic sequence is the only cis-acting element 
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Figure 1.3 : AAV  genome resides between inverted terminal repeat (ITRs), symmetric DNA 
sequences of 145 bases. They contain the Rep-binding element (RBE) and the terminal resolution 
site (trs) that are required for wtAAV genome replication process.  
 
 
wtAAV life cycle depends on the presence of a helper virus superinfecting the host 
cells. Under non-permissive conditions (i.e. without helper virus), the AAV genome 
establishes a latent infection mainly integrating into a specific sequence of human 
chromosome 19q13.3, designated as AAVS1 (Berns and Linden, 1995). A crucial 
role in latency persistence is played by Rep 68/78, which is synthesized at basal 
levels and negatively regulates AAV gene expression and DNA synthesis. The 
latency state, although not altering cell viability, does affect the phenotype as well 
as the expression of specific cellular genes, conferring more sensitiveness to UV-
light, genotoxic agents and heat, enhancing serum requirement and reducing the 
cellular growth rate. It is assumed that all these effects are somehow related to a 
low-level production of the Rep protein (Marcello et al., 2000). Under the presence 
of helper virus, the regulation of AAV gene expression becomes rather complex, 
depending upon both the foreign virus and the presence of Rep68/78 proteins. In 
these circumstances, it could happen that the AAV integrated genome undergoes 
an excision process from the host cell DNA and is packaged into infectious 
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particles. The mechanism underlying the integration process, depending on the 
specific recognition between AAV sequences and the AAVS1 region on 
chromosome 19, is not yet fully understood. Some evidence indicates that this 
region is located close to the human troponin T gene, displaying an overall GC 
content of 65%, a 35-mer minisatellite tandemly repeated for 10 times and a 
putatively transcribed ORF; the possible role of these features in the integration 
process still remains unclear (Dutheil et al., 2000).  A pivotal role in the integration 
and rescue mechanisms is exerted by the viral ITRs, and, in particular, by two short 
sequences (Rep Binding Element, RBE and Terminal Resolution Site, TRS) in the 
stem of the T-shaped structure. These sequences drive the binding of Rep 68/78 
and the subsequent nicking of the viral DNA, a process essential for viral DNA 
replication. Since the same RBS and TRS are also present within the AAVS1 
sequence, a model was proposed that suggests the involvement of an oligomeric 
complex of Rep to juxtapose the RBS and TRS from the cellular and viral DNAs. 
Some studies reported that a portion of wtAAV can also integrate randomly into 
the genome; more specifically, experiments performed in the mouse liver 
demonstrated that 53% of wtAAV integrations are within genes, 27% within 1 kb 
of a transcription start site, and 25% within a CpG island (Ohashi et al., 2005).  
Analysis of integration patterns in primary human fibroblasts transduced with 
rAAV2, disclosed that 38% of the integrations are within the genes, and 4% within 
a CpG island (Inagaki et al., 2007). Studies in which rAAV2 and rAAV8 were used, 
revealed that, in addition to these regions, AAV vectors display a preference for 
integration into ribosomal DNA repeats, and near palindromes with arms being at 
least 20-bp long (Miller et al., 2005). The AAVS1 hotspot represents about 10% of 
the total events of integration; novel hotspots near consensus RBSs were identified 
distributed all over the human genome (Huser et al., 2014). Other hotspots are in 
chromosome 5p13.3 and chromosome 3p24.3 (Huser et al., 2010). (Figure 1.4) It 
should be emphasized that integration of the AAV genome is strictly dependent 
on the Rep gene, or at least on one of its products, the Rep68 or Rep78 proteins. 
Recombinant AAV vectors, devoid of Rep genes, are unable to integrate into the 
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host genome, neither site-specifically nor in a random manner, and their genomes 






Figure 1.4 : Integration hotspots of wtAAV. AAVS2 site is on chr. 5 and AAVS3 on chr. 3. The sites 
display RBS similarly proficient for Rep-binding as AAVS1, the standard site that resides on chr. 19 
(adapted from Huser et al., 2010). 
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1.1.2 Construction and production of recombinant AAV vectors  
 
The characteristics of AAV life cycle, including its defectiveness and ability to 
persist in infected cells as a latent viral genome, early suggested that this virus 
could be an excellent tool for in vivo gene transfer. Since the AAV genome cloned 
into a plasmid is still infectious and able to produce viral particles, any exogenous 
gene (less than 4.5 kb in length) can theoretically be placed within the two 145 bp 
ITRs to obtain a circular backbone suitable for vector production (Gao et al., 1998). 
Unlike other delivery systems that have evolved into several generations, the 
original composition of the AAV vector plasmid (a transgene expression cassette 
flanked by the two ITRs) is essentially the same as in the current version. The 
traditional method for rAAV production is based on co-transfection in adherent 
HEK293 cells of the vector plasmid together with a second plasmid, 
supplementing the rep and cap gene functions, into helper-infected cells, typically 
Adenovirus or Herpesvirus (Figure 1.5) (Laughlin et al., 1983) (Samulski et al., 
1982). To avoid the problem of residual presence of contaminating helper virus in 
purified recombinant AAV stocks, current improved protocols entail the use in the 
production of rAAV of a helper plasmid carrying a few adenovirus genes known to 
be necessary for full AAV amplification (E4, VA and E2a) but lacking the Ad 
structural and replication genes (Gao et al., 1998) (Grimm et al., 2003) (Grimm et al., 
1998). In this way, it is now possible to obtain rAAV preparations free of 
contaminating helper virus and unwanted adenoviral protein at a yield even 
higher than that achieved by using infectious helper virus.  
AAV vector particles are then harvested and purified from cell lysates by 
biochemical procedures and repeated density gradient (typically cesium chloride 
or iodixanol); a purification using ion-exchange chromatography is often used to 
obtain a pure rAAV preparation with the aim to increase its infectivity (Hermens et 
al., 1999; Zolotukhin et al., 2002). Recently, Guo and co-workers developed a 
simplified method using PEG/(NH(4))(2)SO(4) aqueous two phase partitioning that 
claims to be quick and not expensive (Guo et al., 2013). 
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To overcome the dependency on transient transfection, many efforts have been 
put in the establishment of packaging cell lines, similar to those already developed 
for retroviral and adenoviral vector production, but stably containing multiple 
copies of the rep and cap genes. Expression of these genes would be moderate in 
basal conditions, but could be triggered by infection with adenovirus. 
Nonetheless, these efforts have met very limited success so far, mainly due to the 
toxicity of the constitutive expression of Rep, which, even at very low levels, is very 
badly tolerated by proliferating cells (Holscher et al., 1994). Therefore, transient 
transfection still remains the method of choice to obtain AAV vector preparation 
for both investigation and gene therapy purposes. 
An alternative procedure, which has gained significant momentum over the last 
few years, is based on a baculovirus expression vector system in non-adherent 
insect cells grown in bioreactors, with significant methodological simplification 
(Mietzsch et al., 2014). This system appears stable and particularly useful for scaling 
up and production of clinical grade vectors.  
Packaging efficiency seems to depend principally on the cellular system used and 
on the size of the packaged genome. A "head-full" mechanism appears to be used 
by the packaging machinery, with upper and lower limits of 4.9 and 4.1 kb 
respectively for optimal packaging, even if constructs up to 5.2 kb are tolerated.  
(Grimm et al., 1998). Production titers within 1x104 and 1x105 AAV particles per cell 
(as measured by quantifying the number of viral genomes) represent current, 
consistent and probably limiting values, still amenable to scaling up to a certain 
extent by increasing the number of cultured cells. 
 
 
	   21 
  
Fig 1.5. AAV production, triple transfection protocol. The is co-transfected a vector plasmid 
encoding the transgene cassette between the ITRs, an AAV packaging plasmid carrying the rep-cap 
genes and an adenovirus helper plasmid, the rAAV vectors are produced very efficiently. 
 
 
1.1.3 AAV serotypes  
 
Nowadays more than one hundred distinct primate AAV capsid sequences have 
been found. Each of the AAV types has unique serological profiles and has been 
named as a particular AAV particle (Gao et al., 2005). To date, 13 primate serotypes 
(AAV1–13) have been described. The AAV1 and AAV6 capsids differ by only six 
amino acids and, subsequent to their naming, they have been found to be 
serologically indistinguishable. The capsids for which the crystal structures have 
been determined so far are AAV2, AAV4, and AAV8 (Gao et al., 2002).   
Previous work has compared AAV serotypes characterizing their transduction 
efficiency in tissues in vivo (Fig 1.6). In striated muscle, early studies achieved high 
transduction efficiency with AAV1, AAV6, and AAV7. More recently, AAV8 and 
AAV9 have been found to transduce striated muscle with efficiencies at least as 
high.  rAAV8 and rAAV9 are considered to have the highest level of hepatocyte 
transduction (Ohashi et al., 2005). In the pulmonary system, rAAV6 and rAAV9 
transduce much of the entire airway epithelium, while rAAV5 transduction is 
limited to lung alveolar cells. With respect to transduction of the central nervous 
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system, rAAV serotypes 1, 4, 5, 7, and 8 have been found to be efficient transducers 
of neurons in various regions of the brain (Zabner et al., 2000). 
rAAV1 and rAAV5 have also been reported to transduce ependymal and glial cells. 
In the eye, rAAV serotypes 1, 4, 5, 7, 8, and 9 efficiently transduce retinal 
pigmented epithelium, while rAAV5, rAAV7, and rAAV8 transduce photoreceptors 
as well. rAAV1, rAAV8, and rAAV9 have shown the highest reported transduction in 
pancreas tissue, primarily in acinar cells (Inagaki et al., 2006). Kidney seems to be a 
less permissive organ, although proximal tubule cells have been transduced by 
rAAV2 at low levels, and glomeruli were targeted by rAAV9. rAAV1 has been shown 
to transduce adipose tissue, although with the help of a nonionic surfactant 
(Mizukami et al., 2006). The adult heart is one of the tissues most permissive to 
transduction with various AAV serotypes, including AAV1, AAV2, AAV6, AAV8 and 
AAV9. It is noteworthy that AAV1 expressing the SERCA2a gene, a 
sarco/endoplasmic reticulum Ca2+-ATPase, was used to successfully reversed 
cardiac dysfunction in several large animal models. Moreover, AAV1 SERCA2a gene 
therapy revealed an excellent safety profile in a phase I clinical trial and the results 
from a phase II trail have further established the clinical efficacy of type of therapy 
(Bish et al., 2008) (Lyon et al., 2011).  
 
 
Figure 1.6. AAV serotypes allow in vivo targeting of different tissues and organs. AAV tropism 
depend on the capsid composition, these favorable characteristics make AAV a versatile vector for 
gene therapy approaches. (adapted from nature methods 7, 2010).  
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1.1.4 Self-complementary AAV 
 
Self-complementary adeno-associated virus (scAAV) is a viral vector engineered 
from the naturally occurring AAV virus. scAAVs have been designed to overtake 
the single stranded AAV second-strand synthesis, that represent a rate-limiting 
step for efficient transduction (Ferrari et al., 1996). scAAV vector genomes are 
capable to self-hybridize by folding back upon release from the capsid into the 
infected cells, producing an immediate double-stranded (ds) AAV genome (Figure 
1.7).  
This class of vectors has also been reported to result in higher level transduction 
and more rapid onset of transgene expression in several tissue types, including 
liver, retina, brain and muscle (Petersen-Jones et al., 2009) (Fu et al., 2003) (McCarty 
et al., 2001). The scAAV vector genomes are created by removing the TRS site  
(terminal resolution site) from one of the ITRs. When the vector DNA is replicated 
by the rolling hairpin method, the replication machinery binds at a site present in 
the wt ITR and continues towards the mutated ITR. In the absence of a TRS or a 
break in DNA, second strand synthesis continues throughout the mutated ITR and 
back again along the genome using the opposite strand as template. The synthesis 
continues to the end of the wt ITR, which is then resolved at the TRS, resulting in a 
dimeric genome with a mutated ITR in the middle (McCarty et al., 2003). The scAAV 
DNA inside the AAV capsid is compacted in a single-stranded forms (McCarty et al., 
2003). After the viral uncoating, the single-stranded genome is released into the 
nucleus, and the palindromic wild-type ITRs pair up forming a double-stranded 
genome that is immediately ready for transcription. 
Due to its characteristics, the packaging capacity of the scAAV vector is limited to 
approximately 2.1 kb. There are some evidences that indicate that the fate of 
scAAV genome differs from that of ssAAV. The genome conversion step involves 
DNA damage related proteins that collocate scAAV in different DDR related 
pathway, some authors showed that ATR (ataxia telangiectasia and Rad3-related 
protein) blocks the conversion of ssAAV to dsDNA but it does not affect scAAV 
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genomes (Cataldi and McCarty, 2010). Despite the fact that the scAAV genome 
processing is not fully clear and needs further investigation, the potential of scAAV 
vectors at clinical level has been shown in several studies (Wu et al., 2008). 
 
Fig 1.7 Scheme of ssAAV and scAAV genome processing step. rAAV need the DNA second strand 
synthesis step. scAAV genome is capable to do self-annealing becoming immediately double 
stranded and ready to transcribe. 
 
 
1.2 Infection Biology of rAAV vectors 
 
The adeno-associated virus infects the host cell through a mechanism that 
involves these principal steps, represented in Figure 1.8 :  
 
1.  - Binding of the virion to the cellular membrane  
2.  - Internalization of the virion through clathrin coated pits endocytosis 
3.  - Escaping from late endosome 
4.  - Passage through the nuclear pore complex 
5.  - Uncoating from capsid inside the nucleus 
6.  - Genome processing 
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The first step of the infection process is mediated by two different classes of 
cellular receptors. A primary receptor is responsible for the recognition of the 
target cell and the binding of the virus to the cell membrane. In addition, binding 
to a secondary receptor triggers a cascade of events that cause endocytosis and 
internalization of the AAV particles. Heparan sulfate proteoglycan (HSPG) has been 
identified as the primary receptor for AAV2 (Summerford and Samulski, 1998). This 
molecule is present in a wide range of human cell types, explaining the broad 




integrin, human Fibroblast Growth Factor 
Receptor (hFGFR1) have been described as secondary receptors for AAV2 
(Mizukami et al., 1996). While integrin is involved in endocytosis, hFGFR1 seems to 
enhance the attachment process. However, the contribution of these co-receptors 
to AAV2 infection is not completely understood yet  (Summerford et al., 1999). A 
summary of AAV receptor and co-receptor described for the different serotypes is 
reported in Table1. 
 
Virus Glycan receptor Co-receptor/other 
AAV1 N-linked sialic acid Unknown 
AAV2 HSPG FGFR1, HGFR, LamR, CD9 tetraspanin 
AAV3 HSPG FGFR1, HGFR, LamR 
AAV4 O-linked sialic acid Unknown 
AAV5 N-linked sialic acid PDGFR 
AAV6 N-linked sialic acid, HSPG EGFR 
AAV7 Unknown Unknown 
AAV8 Unknown LamR 
AAV9 N-linked galactose LamR 
BAAV Ganglioside GM1 Unknown 
 
Table 1. AAV receptors and preferential tissue tropism. Abbreviations: AAV, adeno-associated virus; 
EGFR, epidermal growth factor receptor; FGFR1, fibroblast growth factor receptor 1; HGFR, 
hepatocyte growth factor receptor; HSPG, heparan sulfate proteoglycan; PDGFR, platelet-derived 
growth factor receptor. Adapted from (Nonnenmacher and Weber, 2012) 
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Figure 1.8. AAV entry steps into HeLa cells. Following attachment to HSPG, AAV is rapidly 
internalized via clathrin-coated pits through a process involving αvβ5 integrin. Once inside the cell, 
an acidic environment allows the penetration of the virus into the cytoplasm. Following endosome 
release, AAV accumulates perinuclearly and slowly penetrates through the NPC into the nucleus 




After binding to the cell membrane, AAV virons are internalized through clathrin-
coated pits mediated endocytosysis that seems to be the predominant, although 
not the exclusive mechanism followed by the virus to traffic to the nucleus.  
Interestingly, there is a conserved region inside the AAV VP1 capsid protein, found 
also in other parvoviruses, which contains a phospholipase A2 (PLA2) motif 
(HDXXY). Little is known about the functional properties of this moiety, but  some 
authors suggest that the phospholipase A2 activity of VP1 may be required for 
viral escape from endosomes (Girod et al., 2002). Relatively fewer data describe the 
trafficking of the virus to the nucleus and where and how viral uncoating occurs. 
Several studies have observed a perinuclear accumulation and subsequent slow 
nuclear entry of fluorescent labeled viral particles (Bartlett et al., 2000). Using a 
single molecule imaging technique, Seisenberger and colleagues described a very 
quick transfer of viral particles to the nuclear area and a very rapid and efficient 
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AAV nuclear entry compared to what was previously reported in the literature  
(Seisenberger et al., 2001). Some experiments showed that AAV transport across 
the nuclear membrane does not seem to depend on active transport through 
nuclear pore complexes (NPC) (Xiao et al., 2002). Recent data, however, 
demonstrate that AAV enters into the nucleus through an active importin-β 
related mechanism (Nicolson and Samulski, 2014). Interestingly, all cellular 
determinants required for viral uncoating and second-strand synthesis are 
contained within the nucleus (Hansen et al., 2001). Some experiments reported 
that nuclear injection of antibody against intact capsids dramatically reduces 
transduction demonstrating that viral uncoating may be a rate-limiting step of 
transduction, dependent in part on AAV serotype (Sonntag et al., 2006). After 
uncoating, AAV genomes have to become double-stranded in order to be 
transcribed. The mechanism by which the single-stranded rAAV genome becomes 
double-stranded is not fully understood. It was generally assumed that host-cell 
polymerases would be involved in second-strand synthesis, due to the fact that, in 
vitro, cells in S-phase are transduced at a rate 200 times higher than non-dividing 
cells. However, agents that damage DNA (such as ultraviolet or γ-radiation) or 
agents that inhibit DNA synthesis (such as hydroxyurea or topoisomerase 
inhibitors) were also reported to increase rAAV2 transduction in vitro (Russell et al., 
1995), suggesting that DNA repair mechanisms may be involved in transduction 
(Jurvansuu et al., 2005). Previous studies described AAV genome second-strand 
synthesis as a rate-limiting step for the viral transduction (Ferrari et al., 1996). 
Experiments performed in vitro and in vivo put in evidence the requirement of 
host cell-mediated second strand synthesis for AAV genome processing, 
demonstrating that a mutant rAAV2 vector genome of single-polarity (obtained by 
mutating the AAV ITR D segment) was proficient for transduction with the same 
efficiency as a standard rAAV2 vector, composed of equal amount of packaged 
genomes of either polarity (Zhou et al., 2008). However, this does not exclude the 
existence of other mechanisms for ssAAV processing. Indeed, there is experimental 
evidence describing that self-annealing of complementary AAV (+) and (-) single 
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stranded genomes also contributes to the generation of double-stranded AAV 
genomes (Nakai et al., 2000).  
 
 
1.2.1 Factors that increase AAV transduction 
 
Experimental evidence from different laboratories has demonstrated both in vitro 
and in vivo the existence of several barriers that may affect AAV transduction, 
including virus internalization, trafficking to the nucleus and genome conversion. 
Early studies have shown that several classes of chemical and physical agents are 
able to enhance AAV transduction (Yalkinoglu et al., 1988). There is experimental 
evidence, for example, that different classes of proteasome inhibitors increase 
transduction by multiple AAV serotypes, both in vitro and in vivo, enhancing the 
rate of viral translocation to the nucleus (Yan et al., 2002). It is likely that the viral 
capsid undergoes a ubiquitination process, since the inhibition of ubiquitin ligase 
E3 is able to induce an enhancement of rAAV2 transduction (Yan et al., 2002). 
Although the mechanisms by which these drugs increase transduction have not 
been fully elucidated, these findings suggest that proteasome-mediated 
degradation may represent a significant limitation of AAV-mediated transduction 
(Yan et al., 2004). Work from different laboratories has demonstrated that 
genotoxic agents that lead to a DNA damage response (DDR) in the host cell, such 
as hydroxyurea (HU), doxorubicin (DOXO), and camptothecin (CAMPTO), are also 
capable to increase AAV transduction (Russell et al., 1995). Previous findings from 
our laboratory showed that DNA repair proteins belonging to the MRN complex, 
Rad50, NBS1, MRE11, are able to inhibit AAV infection (Cervelli et al., 2008); 
furthermore, a collaborative work with the M. Weitzman group demonstrated that 
the adenovirus protein E4-orf6 helps AAV transduction triggering the degradation 
of MRE11, a crucial protein of the MRN complex (Schwartz et al., 2007). One 
hypothesis is that the DDR proteins block incoming single stranded AAV genomes 
and that an induced massive DDR diverts the inhibitory proteins away from viral 
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DNA to other damaged host genome sites (Cervelli et al., 2008). Samulski and co-
workers proposed an additional model to explain HU enhancing effect, showing 
that cell treatment with this drug increases the mobilization into the nucleoplasm 
of AAV virons initially accumulated into nucleoli; the release of viral particles may 
accelerate the un-coating process. Interestingly, some HDAC inhibitors were also 
able to increase AAV transduction. It was demonstrated that the acetylated 
histones associated with the AAV genome could play a role in AAV transgene 
expression, while other experiments demonstrated that rAAV promoter 
methylation state does not influence viral transduction (Okada et al., 2006) (Leger 






1.3.1 Histone octamer 
 
Histones are the primary proteins associated with the DNA in eukaryotes. The key 
unit of chromatin is represented by the nucleosome, which is composed of a 
histone octamer wrapped around with a 147 bp DNA in 1.65 left-handed super-
helical turns (Luger et al., 1997). Core histones are four proteins called H2A, H2B, 
H3 and H4 that compose the histone octamer. The histones H1 and H5 are known 
as the linker histones, which bind the nucleosome at the entry and exit sites of the 
DNA, thus locking the DNA into place and allowing the formation of higher order 
structure (Allan et al., 1981). The sequence similarity is low between the core 
histones, but each of the four proteins has a conserved structure consisting of 
three α-helix called the histone fold motif (Arents et al., 1991). 
The role of histones in packaging the chromosomal DNA was described the first 
time in 1974 (Kornberg, 1974); these proteins are responsible for the 40,000 times 
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compaction of a DNA molecule, necessary to fit the large eukaryotic genomes 
inside the cell nuclei. The histone octamer interacts with the DNA minor groove 
and this interaction is prevalent with A:T enriched regions than G:C enriched 
regions (Shrader and Crothers, 1990). 
During that last decade, different laboratories have contributed to the 
characterization of many post-translational modifications of histone proteins, such 
as methylation, acetylation, phosphorylation, ubiquitination, SUMOylation, 
citrullination, ADP-ribosylation; these modifications seem to play key roles in the 
modulation of chromatin folding and regulation of the accessibility of the DNA to 
factors involved in transcription, replication, recombination and repair (Ito, 2007). 
The discovery of the histone post-translational modifications has supported the 
so-called “histone code” hypothesis that the genetic information could be partially 
regulated by the chemical variations of histones  (Jenuwein and Allis, 2001).  
Despite their resistance to DNA dissociation due to their positive electrical charge, 
nucleosomes are not static factors but can shift along DNA. Access to nucleosomal 
DNA is governed by two major classes of protein complexes: the covalent histone-
modifying enzymes and the ATP-dependent chromatin remodelling factors. 
Chromatin remodelling is defined as the enzyme-assisted process to facilitate 
access to nucleosomal DNA by remodelling the chromatin structure, it has a role in 
crucial biological processes, like apoptosis, chromosome segregation, 





1.3.2 Histone deposition 
 
Nucleosome assembly following DNA replication, DNA repair and gene 
transcription is critical for the maintenance of genome stability and epigenetic 
information. All four core histones (H2A, H2B, H3, H4) contain about one forth of 
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positive charged residues such as lysine and arginine, and this characteristic 
endows these proteins with great DNA affinity and binding capacity. For these 
reasons, the process that couples histones to DNA is tightly regulated by the cell in 
order to avoid their potential toxicity due to their strong affinity to negatively 
charged nucleic acids. Work performed in vitro showed that the first event in the 
nucleosome assembly on replicating DNA is the deposition of an H3–H4 tetramer, 
which is rapidly followed by deposition of two H2A–H2B dimers (Smith and 
Stillman, 1991). Histone chaperones are key proteins that act at multiple steps of 
nucleosome formation. H3 histone is deposited onto DNA by the histone 
chaperone CAF-1. CAF-1 is the major factor that orchestrates replication-coupled 
nucleosome assembly and is composed of p150, p60, and p48 subunits 
(Marheineke and Krude, 1998). The histone H3 variant H3.3, differing from 
canonical H3 by four or five amino acids, is deposited, together H4 histone, by the 
HIRA histone chaperones in replication-independent manner (Tagami et al., 2004).  
There is some evidence that indicates that chromatin restoration after DNA 
damage cannot rely simply on histone recycling and that new histone 
incorporation at repair sites should be present. Polo and co-workers showed, for 
example, the occurrence of a CAF-1 mediated new histone deposition upon UV 
irradiation in human cells (Polo et al., 2006). 
 
 
1.3.3 Histone gene expression and mRNA metabolism 
 
The organization of histone genes into clusters is evolutionary conserved from 
yeast to humans. Histone gene clusters in mammals are heterogeneously 
organized and contain one or more copies of the five histone subtypes. The 74 
known human histone genes can be found within the major and minor clusters 
located on chromosomes 6p21 and 1q21, respectively (Schaffner et al., 1978). In 
the mouse, there are 65 distinct canonical histone mRNAs, which code for the five 
types of canonical histone proteins (Marzluff et al., 2002). These histone mRNAs are 
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the only known metazoan mRNAs that are not polyadenylated but contain a 
unique 3’ end stem-loop structure. Transcriptional activation of histone subtypes is 
co-ordinately regulated and tightly coupled with the onset of DNA replication 
during the S-phase, when histone gene transcription is induced approximately 5-
fold (DeLisle et al., 1983). It was reported that the E-Cdk2 substrate NPAT plays an 
essential role in the transcriptional activation of histone genes at the G1/S-phase 
transition (DeRan et al., 2008). In the same way, after S-phase completion, histone  
mRNAs encoded by replication-dependent histone genes must be rapidly 
degraded. Conversely, the transcripts of the replication-independent histone 
variants are polyadenylated and their synthesis persists also outside S-phase.  
The genes encoding metazoan canonical histones lack introns, and thus one 
endonucleolytic cleavage reaction is the only processing event necessary to form 
mature histone mRNA. Cleavage requires binding of the stem-loop binding 
protein (SLBP) and is carried out by a multi-component machinery containing U7 
snRNP (Mowry and Steitz, 1987). SLBP remains bound to the histone mRNA as it 
relocates to the cytoplasm, where histone mRNA is circularized through a complex 
of proteins including at least SLBP, SLBP-interacting protein 1 (SLIP1) and 
eukaryotic translation initiation factor 4-γ (EIF4G). Subsequently, translation of 
histone mRNA takes place. At the end of S-phase, a short U-tail is added to histone 
mRNA in the cytoplasm. The LSM1–7 ring complex binds the oligo(U) histone 
structure to cooperate with a conserved complex of 3’ to 5’ exonucleases that 
degrade the histone mRNA. The 3'-5' exoribonuclease 1 or Eri1 has been 
characterized for its ability to bind the 3'-end of histone mRNAs and to degrade 
them, after replication (Herrero and Moreno, 2011) (Hoefig et al., 2013). In addition, 
the cyclin A/cyclin-dependent kinase 1 complex (CycA/CDK1) phosphorylates SLBP 
to trigger its degradation; this event avoids the accumulation of histone mRNAs 
and, eventually, histone proteins (Marzluff et al., 2008). 
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1.3.4 Chromatin remodeling in DNA double strand break repair 
 
The role of chromatin in the responses to DNA double strand breaks represent 
today one of the most intriguing fields of basic research investigation. An efficient 
DNA double strand breaks repair system requires a complex organization of 
chromatin, since the nucleosome structure represents a huge obstacle to the 
efficient detection and repair of DNA lesions.  
A DNA double strand break can be repaired through two main mechanisms: non-
homologous end-joining (NHEJ), which is error-prone, and homologous 
recombination (HR) (Lukas and Bartek, 2009) (Huertas, 2010).  
NHEJ requires the Ku70/80 DNA-binding complex and the DNA-PK catalytic 
subunit (DNA-PKcs), which allows the non-homologous and quick junction of the 
DNA ends. This system is the predominant double-stranded DNA break repair 
pathway in mammalian cells. Some authors showed that the NHEJ pathway in 
yeast is favoured by H3K36 methylation; this histone modification reduces 
chromatin accessibility, decreasing the DNA end-resection process that belongs to 
the HR pathway (Pai et al., 2014). Homologous recombination is more complex 
and requires the processing of single-stranded DNA (ssDNA) intermediates, which 
is used to search for the homology within adjacent sister chromatids. The 
production of ssDNA requires the initial nuclease activity of the MRN complex 
(Sartori et al., 2007) followed by further DNA end-processing by additional 
nucleases to produce ssDNA intermediates (Symington and Gautier, 2011).  
The MRN complex, consisting of the MRE11, RAD50, and NBS1 proteins, is the first 
sensor of double strand breaks (DSBs)., which functions to recruit and activate the 
ATM/ATR complex (Paull and Lee, 2005). Activated ATM/ATR then phosphorylates, 
through a cascade, several target proteins, including factors involved in 
checkpoint activation (p53 and chk1/chk2) and DNA-repair proteins such as BRCA1 
and 53BP1 (Chen and Poon, 2008). A critical target for ATM is phosphorylation of 
the C terminus of the histone variant H2AX, one of the most common histone 
modification signature characterizing the DDR.   
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In 1998, the group of Rogakou described for the first time the involvement of the 
histone variant H2AX and its phosphorylation at the serine139 residue in the DDR 
process (Rogakou et al., 1998).  Subsequently, phosphorylation of H2AX by ATM 
spreads away from the DSB, creating γ-H2AX domains that extend for hundreds of 
kilobases along the chromatin from the DSB (Rogakou et al., 1999).  
Histone acetylation is another common histone modification related with both 
transcription and DNA damage. Histone acetylation neutralizes positively charged 
lysine residues, thus altering histone-histone interactions to promote chromatin 
decondensation favouring the access to nucleosomal DNA (Kouzarides, 2000). 
Acetylation at the H3 and H4 tails, such as ac-H3K56, plays a critical role in DNA 
metabolism involving DNA replication, genomic stability and in the binding of the 
chromatin assembly factor (CAF1)-PCNA complex (Chen and Tyler, 2008). 
Literature reports that acetylated H3 and H4, induced by CBP and p300, cooperate 
with the SW1/SNF complex to facilitate recruitment of NHEJ proteins such as 
Ku70/80 (Ogiwara et al., 2011). During HR, a number of acetylation events occur on 
histones H3 and H4 involving a large number of factors such as GCN5, NuA4 and 
HAT1 (Murr et al., 2006).  
Histone methylation on lysine and arginine was discovered more than fifty years 
ago (Murray, 1964). Histone methylation is often related with transcriptionally 
repressed chromatin but an histone methylation code associated with DNA 
damage was also described. During DDR, methylation occurs at multiple sites on 
H3 and H4 (mono- di- and trimethyl groups per residue) including K4, K9, K27, K36, 
K79 and R2, R8, R17, R26 for H3 and K20 and R3 for H4 (Ferrari and Pasini, 2013). 
The source of the methyl group required by histone methyl-transferases is S-
adenosyl-methionine; presence of a SET domain characterizes several proteins 
belonging to this class of enzymes (Trievel et al., 2002). In mammals, dimethylation 
of histone H4 lysine 20 (H4K20me2), is induced by the MMSET enzyme and this 
process seems to be critical for the recruitment of 53BP1 in vicinity to DSBs. 
Interestingly, MMSET methyl-transferase depletion significantly decreases H4K20 
methylation at DSBs, as well as 53BP1 accumulation at damaged DNA sites (Pei et 
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al., 2011). SETD8, an enzyme that mono-mehtylates lysine H4 residue K20 is also 
present on the double strand break sites; H4K20me1 is enriched during mitosis 
and represents a specific tag for epigenetic transcriptional repression (Dulev et al., 
2014). Metnase is another methylase that dimethylates histone H3 residue K36 
(H3K36me2) at the DNA DSB site; the levels of H3K36me2 were found to correlate 
positively with DSB repair efficiency (Povirk, 2012). Another histone modification, 
H3K4me3, induced by SET1 methyltransferase has been found at DNA DSBs, and 
the absence of this modification was associated with defective DNA DSB repair 
(Faucher and Wellinger, 2010). 
Similar to other conserved DNA repair mechanisms, ubiquitylation is also a tightly 
regulated event involving the enzymatic activity of E1, E2 and E3 proteins (Hershko 
and Ciechanover, 1998). Ubiquitination of nuclear histones occurs after DBS 
induction by RNF8, and RNF168, two E3 ubiquitin-protein ligases, which catalyse 
formation of lysine 63 linked polyubiquitination chains on histones H2A and H2AX 
(Doil et al., 2009). Another important ubiquitination event during DDR is induced 
by the BRCA1 E3 ligase, which promotes BRCA2 binding that subsequently triggers 
RAD51 recruitment during DNA strand resection in the DNA HR repair pathway 
(Qing et al., 2011). Moreover, some authors reported that the UBC13 E3 ligase is 
required for HR itself. In particular, Zhao and co-workers showed that cells lacking 
UBC13 are defective in break resection as determined by RPA recruitment to DNA 
DSBs (Zhao et al., 2007).  
The histone code describing the interplay between chromatin and the DDR is 
complex and each molecular signature is not univocal. Histone modification after 
the DDR induced by DSBs reflects changes in chromatin composition and 
compaction. For example, some experiments showed that DNA DSBs can induce 
chromatin decondensation and that this is an actively regulated process (Ziv et al., 
2006). A global increase in chromatin accessibility in response to UV damage was 
also reported (Carrier et al., 1999).  On the other hand, DSBs can lead to a 
repressive chromatin state; heterochromatin displays specific histone 
modifications, such as di- or tri-methylation of histone H3 at lysine 9, and the 
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subsequent recruitment of chromatin association proteins such as 
heterochromatin protein1 (Hp1) (Cheutin et al., 2003). Some authors showed that 
a complex containing the suv39h1 methyltransferase is rapidly recruited to DSBs, 
where it directs H3K9 methylation on large chromatin domains adjacent to the 
DSB (Ayrapetov et al., 2014). 
There is also multiple evidence indicating that CAF-1, the major H3/H4 histone 
chaperone, plays a role in setting up a repressed chromatin state after a DNA 
damage signal. Some authors reported that propagation of silenced chromatin is 
intimately linked to the histone deposition process, moreover, loss of CAF-1 
function causes heterochromatin abnormalities and loss of viability during 
development in mouse, Xenopus  and Drosophila (Quivy et al., 2001) (Moggs et al., 
2000). However, the precise effect that the overall compaction status of chromatin 
exerts on the access, signaling, and repair of DNA damage is not known. 
Understanding the chromatin changes during the DDR still remains a central topic 
for investigation. 
As far as the DDR is concerned, the most common histone modifications are  
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1.3.5 Chromatin as an anti-viral defense mechanism 
 
In recent years, several investigations have highlighted the importance of 
chromatin during viral infection. It is now clear that the chromatinization of viral 
genomes should be considered part of the host defense to invading pathogens. 
The interplay between viral and host chromatin determines the outcome of viral 
infection and regulates viral latency and reactivation by modulating gene 
expression, impeding genome conversion or inducing epigenetic repression.  
For example, it is known that treatment with HDAC inhibitors stimulates 
transcription from many viral promoters, including the CMV promoter (Murphy et 
al., 2002). This mechanism was also described for the reactivation of Herpes 
simplex 1 and Epstein-Barr viruses from latency, suggesting a role for HDACs in the 
silencing of latent viral genomes.  
Cells have also developed mechanisms against retroviruses that act through 
creating a repressive chromatin state on the viral genome. For example, the host 
positive transcription elongation factor p-TEFb triggers the methylation of histone 
H3 Lys4 and Lys36 during reactivation of latent HIV genomes. This event suggests 
that the P-TEFb kinase activity plays an important role in regulating downstream 
chromatin modifications, such as histone methylation during HIV-1 transcription 
elongation (Zhou et al., 2004). Thus, quite paradoxically, this represents a cellular 
defense mechanism that contributes to HIV viral latency and persistence.  
More recently, several experiments have demonstrated the pivotal role that 
chromatinization exerts in HIV viral gene expression. Protein complexes involved 
in chromatin remodeling, including histone acetyltransferases, can activate HIV-1 
gene expression both in vitro and in vivo. Agents such as polyamides, which 
interacts with the HIV promoter  by blocking HDAC-1 recruitment, and trichostatin 
A, a HDAC inhibitor, have striking positive effects on HIV gene activation 
(Ylisastigui et al., 2004) (Quivy et al., 2002). 
Also Adenovirus (Ad) does not escape the chromatinization process. Indeed, six 
hours post infection approximately 50% of adenoviral DNA is associated with 
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nucleosomes (Ross et al., 2011), which control gene expression and stability. In 
chromatin immunoprecipitation studies, helper-dependent adenovirus (hdAd), 
both E1-deleted adenovirus and wild type adenovirus DNA are associated with 
H3.3, a histone variant that marks open chromatin. H3.3 association with the 
adenoviral genomes occurs after four hours after infection, which suggests that a 
replication-independent mechanism is responsible for the assembly of chromatin 
on the viral DNA (Ross et al., 2011). Recent work performed by Komatsu et al. 
(Komatsu and Nagata, 2012) showed that the silencing of CAF-1, the main cellular 
histone chaperone, does not affect histone deposition on the adenovirus genome. 
This finding supports the idea that H3.3 is overrepresented on the Ad viral 
genome. Recent studies have suggested that the rapid deposition of H3.3 
mediated by the HIRA histone chaperone may be an evolved mechanism to 
protect “naked” DNA from damage (Schneiderman et al., 2012) and that this 
strategy might be exploited by adenovirus to avoid the inhibition that DNA repair 
proteins can impose on the incoming viral genomes. 
Infection of cells with wild-type adeno-associated virus was able to trigger pan-
nuclear activation of γ-H2AX, but not of recombinant AAV vectors. This effect 
indicated that the phosphorylation was due to a component of the wild-type AAV 
genome and not the viral capsid (Schwartz et al., 2009) (Fragkos et al., 2008). The 
phosphorilation of γ-H2AX by wild-type AAV was detected onto the p5 promoter 
region, which acts as a potential viral origin of replication (Schwartz et al., 2009). 
Other experiments showed that the DDR response during wt AAV infection was 
much more intense in the presence of helper Adenovirus (Fragkos et al., 2008). R.O. 
Snyder and co-workers demonstrated that the episomal AAV genomes can 
assimilate into chromatin with a typical nucleosomal pattern in vivo (Penaud-
Budloo et al., 2008). Their work suggests that the AAV chromatin structure is 
important for episomal maintenance of AAV genome and, consequently, for 
prolonged transgene expression and persistence of the vector in quiescent tissues. 
Okada and colleagues demonstrated that an histone deacetylase inhibitor, 
FR901228, increased AAV transduction both in vitro and in vivo. These results 
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suggest that the superior AAV transduction obtained following HDAC inhibitor 
treatment may be related to the histone-associated chromatin form of the AAV 
genomes in transduced cells; a cellular immunity defense mechanism aimed to 
inhibit single stranded DNA viruses at the chromatin level might thus be 
postulated to exist  (Okada et al., 2006). 
It is also interesting to consider that one of the major obstacles to success in non-
viral gene therapy is the transcriptional silencing of the naked DNA vector. Some 
evidence showed that changes in the pattern of histone modifications were 
related to the observed transcriptional silencing of exogenous DNA vectors (Riu et 
al., 2007). The mechanisms underlying gene silencing/repression of exogenous 
DNA in mammalian cells appear complex and definitely need further investigation. 
 
 
1.4 The Eri1 exoribonuclease 
 
Eri1 is a protein of 349 residues with an amino-terminal SAP domain and a 
carboxy-terminal 3’ exonuclease domain able to degrade RNA.   
The SAP domain is composed of 35 residues containing an invariant glycine and a 
conserved distribution of hydrophobic, polar and bulky amino acids. The SAP 
domain is present in a number of eukaryotic proteins in conjunction with other 
domains that link these proteins with the RNA or DNA metabolism (Aravind and 
Koonin, 2000). Eri1 elicits its nuclease activity in the presence of riboadenine-5’-
monophosphate and Mg2+ ions (Cheng and Patel, 2004) (Figure 1.10). 
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Figure 1.10 Eri1 structure. Eri1 binds the 3'-end of histone mRNAs in a stem-loop structure 
containing the “ACCCA” consensus sequence. Eri1 degrades histone RNAs and small RNAs through 
its carboxy-terminal 3’ exonuclease domain.  The 3′ flanking sequence of the SL RNA is located in 
the 3′hExo active site. (A) Stereopair showing interactions of the 3′ flanking sequence of the SL RNA 
(orange) with the active site of the Eri1 nuclease domain (green). The bound positions of AMP 
(gray) and two metal ions (pink spheres) to the nuclease domain of Eri1, as observed earlier, are 
also shown (21). (B) Molecular surface of the active-site region of Eri1 colored according to 
electrostatic potential. The SL RNA is shown as a stick model (orange). The black arrow indicates 
another opening from the active site, through which Eri1 may accommodate longer RNA 
molecules. (C) Eri1 protein domain composition (D) Overlay of the structures of the ternary (SL-




The Eri1 nuclease domain shows an α/β globular fold conformation. In the active 
site, residues D134, E136, D234 and D298 and H293 define the core responsible for 
the hydrolytic RNA cleavage in the 3’-5’ direction (Cheng and Patel, 2004). The 
nuclease domain is similar to that found in the 3’ exonucleases of the DEDD-family, 
including both DNA- and RNA-specific enzymes, and is characterized by the 
presence of these four invariant acidic amino acids from which the family name 
originated (Zuo and Deutscher, 2001). Eri1 exoribonuclease binds the 3'-end of 
histone mRNAs and degrades them, suggesting that it plays an essential role in 
histone mRNA decay after replication (Hoefig et al., 2013). A 2' and 3'-hydroxyl 
N-ter C-ter1 76 110 133 331 3493’EXOSAP
A B
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groups at the last nucleotide of the histone 3'-end is required for efficient 
degradation of RNA substrates. Eri1 is also able to process the 3'-overhangs of 
short interfering RNAs (siRNAs), suggesting a possible role as regulator of RNA 
interference (RNAi), (Kennedy et al., 2004). Some experiments demonstrated that 
Eri1 also binds the 5.8s ribosomal RNA and it is required for 5.8S rRNA 3'-end 
processing (Ansel et al., 2008). 
 
 
1.4.1 Eri1 regulates RNA interference 
 
Another described function of Eri1 is to bind and degrade the 3’-overhangs of 
short interfering RNAs and to function as a negative regulator of the endogenous 
RNA interference (RNAi) machinery (Kennedy et al., 2004). In support of this 
activity, G. Ruvkun and colleagues showed that worms with Eri1 mutations 
accumulated more siRNAs after exposure to dsRNA or siRNAs than wild-type 
animals. Moreover, mass-spectrometry data revealed that Eri1 is present in the 
DICER complex, and that it is required for the generation of endogenous siRNAs in 
C. elegans (Duchaine et al., 2006). In the model proposed by Kennedy and co-
workers, Eri1 is able to recruit endogenous RNAs and lead to the cleavage of 3’ end 
of them; after this step, an RNA-dependent RNA polymerase is involved in the 
synthesis of double stranded RNA species that will be cleaved by DCR-1 and 
subsequently introduced into the RNAi-pathway. This model implies that the lack 
of Eri1 impedes the endogenous siRNA production; indeed, exogenously 
introduces siRNAs showed an increased effect in worms with inactive Eri1 
(Kennedy et al., 2004). Consistent with these observations, other studies have 
documented the involvement of the protein in limiting the heterochromatin 
assembly mediated by RNAi in fission yeast by degradation of nuclear siRNAs (Iida 
et al., 2006). More recently, Eri1 was also described to limit the expression of 
global, mature miRNAs in mouse T and NK cells (Thomas et al., 2012). 
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1.4.2 Eri1 processing of ribosomal RNA 
 
Ribosomal RNA (5.8S rRNA) is one of the conserved targets of Eri1. Although most 
ribosome processing happens in the nucleolus, Eri1-mediated 5.8S rRNA trimming 
is likely to occur in the cytoplasm (Gabel and Ruvkun, 2008) (Ansel et al., 2008). 
Although the function of 5.8S rRNA30 trimming is poorly understood, it is likely to 
be important because it is conserved even in Saccharomyces cerevisiae, in which 
an unrelated endonuclease, Ngl2, performs the same function (Faber et al., 2002). 
One hypothesis is that Eri1 binds intact cytoplasmic ribosomes as a way to home 
to the basal translation machinery its enzymatic functions, such as the inhibition of 
RNAi. Interestingly, Eri1 is just one of the several ribosomal RNA processing 
proteins recruited into regulatory small RNA pathways. Alternatively, the function 
of Eri1 in ribosome maturation and miRNA turnover may be purely coincidental, 
because 3’-end trimming is a relatively common post-transcriptional modification 
required for the biogenesis of many unrelated non-coding RNAs. To date, a 
connection between Eri1-dependent rRNA processing and altered epigenetic gene 
regulation remains purely speculative.  
 
 
1.4.3 Eri1 binds the stem loop of histone mRNAs 
 
Histone mRNAs contain a highly conserved 26-nucleotide sequence that forms a 6-
nucleotide stem and a 4-nucleotide loop structure, characterized, among 
vertebrates, by the presence of the “ACCCA” sequence (Yang et al., 2006).  
Dominski and colleagues showed that Eri1 could bind oligos mimicking this 3’ 
stem loop of canonical histone mRNAs in vitro (Dominski et al., 2003).  Subsequent 
studies have demonstrated that Eri1 targets histone mRNA sequences through its 
SAP domain (Yang et al., 2006). In 2006, Cheng and co-workers solved the crystal 
structure of Eri1 in complex with stem loop RNA; their data suggested that the SAP 
domain is indispensable for binding histone RNA (Cheng and Patel, 2004). 
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Functional assays supported this evidence, showing that, by mutating the SAP 
domain, it is possible to abolish the binding of Eri1 to stem loop-RNA structure 
(Yang et al., 2006). 
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The aim of this PhD thesis was to study and understand the cellular mechanisms 
that regulate Adeno-associated virus transduction. This work was performed 
exploiting high throughput screening technologies. Taking advantage of genome-
wide siRNA libraries it was possible to identify some relevant cellular factors that 
mediate rAAV2 transduction. The work described in this thesis is divided into two 
sections. The first part focuses on the characterization of the top-10 siRNAs 
identified in a screening, performed in HeLa cells, for siRNAs increasing rAAV 
efficiency and therefore targeting factors inhibitory on rAAV transduction. This 
part of the research highlights the mechanisms underlying a correlation between 
AAV infection and cellular checkpoint activation. The second part of the thesis 
focuses on the study of factors required for rAAV infection. In particular, we 
characterize the mechanism of action of Eri1, a 3’-exoribonuclease known to 
degrade endogenous miRNAs and histone mRNAs, on AAV transduction. We 
determined that Eri1 is essential for ssAAV but not scAAV transduction and that 
this effect is specifically exerted by changing the AAV genome chromatin 
composition through the modulation of the cellular histone dosage. 
The findings described in this thesis may foster the development of druggable 
siRNA molecules or pharmacological strategies specifically aimed at improving 
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2. Results I 
 
         
 
2.1 High-throughput, genome-wide siRNA screening reveals 
cellular factors critical for AAV transduction 
 
Over the last few years, viral vectors based on AAV have gained increasing 
popularity due to several favourable characteristics, including the excellent safety 
profile, lack of inflammatory response, prolonged transgene expression, relative 
genetic simplicity and high efficiency of transduction of post-mitotic tissues such 
as muscle, heart, brain and retina. Nonetheless, it has become evident that 
significant improvements need to be achieved before attaining broader clinical 
application. Given the molecular simplicity of AAV vector particles, all the 
determinants of permissivity to vector transduction appear to reside among the 
molecular features of the host cell. For this reason, the identification of the cellular 
proteins that regulate vector transduction is an essential requisite to improve in 
vivo transduction, expand the number of permissive tissues and achieve AAV-
mediated gene correction at a clinically applicable level (Carter, 2005). 
To systematically identify the host cell factors involved in the internalization, 
intracellular trafficking, processing of AAV genome and, eventually, AAV gene 
expression, either positively or negatively, we have performed a high-throughput 
screening using a genome-wide siRNA library (18175 human gene targets). We 
assessed differences in AAV transduction in HeLa cells; 48 h after transfection with 
the siRNA library cells were infected using a recombinant single-stranded (ss) 
AAV2 vector expressing the firefly Luciferase reporter gene. Cells were transduced 
at a multiplicity-of-infection (moi) of 2500 viral DNA genomes (vg)/cell, since it was 
estimated that this allows one to achieve a sub-saturating levels of transduction 
optimal for the detection of both positive and negative regulators  (Figure 2.1).   
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Figure 2.1 AAV transduction high-throughput screening setup. The screening was performed in 
HeLa cells, using human a genome-wide siRNA library; each siRNA mixture was composed by a 
pool 4 siRNAs targeting each single gene of human genome. Cells were silenced for 48 h and 
subsequently infected with an AAV expressing the firefly luciferase gene for 24 h. The measure of 
luciferase activity was used to quantify AAV infectivity. Finally, the luciferase readout was 
normalized for cell viability. 
 
 
Analysis of the results obtained from this primary screening identified 1528 genes 
affecting transduction by AAV vectors by more than 4-fold (184 genes by more 
than 8-fold). 
 Of these genes, 993 were inhibitors of AAV transduction, whereas 535 were 
required for efficient transduction. Short interfering RNA pools decreasing cell 
viability to less than 75% were considered toxic, and were thus excluded from 
further analysis; these included siRNAs against well-known, essential genes (e.g. 
UBB, UBC, COPB1, PLK1). Remarkably, the 10 top scoring siRNA pools increased or 
decreased ssAAV2 transduction by as much as 50- and 10-fold, respectively. 
The effect of these genes on AAV transduction was further confirmed in a 
secondary screening based on high-content microscopy analysis using siRNAs 
against the 1,486 genes that affected ssAAV2 transduction by more than 4-fold in 
the primary screening. In this case, HeLa cells stably expressing EGFP under the 
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CMV promoter were transfected with the siRNAs of interest and transduced, 48 h 
later, with a ssAAV2 vector expressing the red fluorescent protein DsRed (ssAAV2-
DsRed). This validation strategy was designed in order to recognized the siRNAs 
affecting expression from the CMV promoter rather than AAV transduction itself.  
We selected the siRNA pools that increased or decreased the percentage of DsRed 
positive cells of more than 4-fold, when compared to cells treated with a control 
siRNA. The siRNAs that decreased EGFP expression were removed from our 
candidate list . 
 
 
Figure 2.2 Distribution of the effects of siRNAs regulating AAV transduction. The screening 
identified 993 genes inhibitory of AAV transduction, the knockdown of which increased 
transduction from 4 up to 50 folds.  
 
 
Gene ontology analysis of the inhibitory genes revealed a clear overrepresentation 
of genes related to DNA recombination and repair and cell cycle control, whereas 
the subset of genes required for infection were enriched in genes involved in 
endocytosis, intracellular trafficking and transcription (Figure 2.2). Consistent with 
our previous results, among the genes that restricted AAV transduction, we found 
members of the MRN complex and other genes involved in the cellular DDR, as 
well as genes involved in the ubiquitin-proteasome system. In addition, a 
significant number of genes were identified, which had not previously been 




Cell growth and proliferation 
DNA replication, recombination 
and repair 
Gene expression 
Cell signaling  
1528 genes a!ect AAV by more than 4-fold
184 genes a!ect AAV by more than 8-fold
(up to 50 folds) 
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associated with AAV transduction.  
The 10 siRNAs that were most effective at increasing AAV transduction genes 
belonging to different families. Interestingly, seven out of ten of these factors are 
involved in cell cycle regulation and DNA repair and have a nuclear localization.  In 
addition, some of them (SETD8, CASPBAP2, NPPAT and CAF-1) are involved in 
chromatin remodeling pathways (Congdon et al., 2010) (Hummon et al., 2012) 
(DeRan et al., 2008) (Houlard et al., 2006) (Figure 2.3). 
 
 
Figure 2.3 List of the top 10 siRNAs increasing AAV transduction discovered in the screening. The 





N° Gene Entrez gene name 
Efficiency of 
transduction  
(fold over control) 
1  SETD8  SET domain containing (lysine methyltransferase) 8 51.4 
2  CASP8AP2 Caspase 8 associated protein  30.2 
3  SOX15  SRY (sex determining region Y)-box 15 27.0 
4  TROAP  Trophinin associated protein (tastin) 25.1 
5  NPAT  Nuclear protein. ataxia-telangiectasia locus 23.6 
6  PHC3  Polyhomeotic homolog 3 (Drosophila) 23.1 
7  CHAF1A Chromatin assembly factor 1 subunit A (p150) 20.9 
8  SF3B1 Splicing factor 3b. subunit 1 155kDa 20.5 
9  RTBDN Retbindin 19.3 
10  BOMB WW and C2 domain containing 2 19.2 
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2.2 Correlation between rAAV infection and DNA damage 
 
Long standing evidence indicates that viral DNA can be recognized inside the host 
cell by the DDR machinery and that genotoxic damage increases cellular 
permissivity to AAV (Yalkinoglu et al., 1988) (Russell et al., 1995). In addition, 
different laboratories, including our own, have previously shown that proteins of 
the DDR, in particular those of the MRN (MRE11-RAD50-NBS1) (Zentilin et al., 
2001), inhibit AAV transduction in both cell culture (Cervelli et al., 2008) and 
primary cells in vivo (Lovric et al., 2012). 
 
 
Figure 2.4 The “titration model” to explain AAV permissivity. This model proposes that genome 
DNA double strand breaks are capable to engage and sequester a large amount of nuclear DNA 
repair proteins, leading to a context in which the single-stranded AAV genome is converted more 
efficiently to double-stranded DNA. 
 
 
Following these considerations, we decided to investigate whether the top ten 
siRNAs of our primary screening exerted any effect on cellular DNA damage, in the 


















Cervelli et al., 2008 
Lovric et al., 2012 
DNA DAMAGE 
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We first analyzed the phosphorylation of histone H2AX at serine 139 (ɣ-H2AX), a 
hallmark of cellular DNA damage (Rogakou et al., 1998), in HeLa cells treated with 
the selected siRNAs. Remarkably, downregulation of six of these genes, at a 
different extent, was able to increases ɣ-H2AX phosphorylation, with SETD8, 
CASP8AP2 and BOMB being the most effective. (Figure 2.5). In the same 
experimental conditions, a non-targeting siRNA was not able to induce any ɣ-
H2AX activation (western blot not shown).  Immunofluorescence experiments 
using an antibody against ɣ-H2AX also confirmed the formation of nuclear foci 
after cell treatment with selected siRNAs from the top 10 inducing AAV 
transduction  (Figure 2.6). 
Taken together, these results indicate that several of the siRNAs inducing cellular 
permissivity to AAV can do so by inducing DNA damage. 
 
 
Figure 2.5. (Panel A) The top 10 siRNAs increasing AAV transduction determine DNA damage, as 
revealed by ɣ -H2AX histone positivity. The western blot demonstrates that, at a different extent, six 
out of the top10 siRNAs induce the phosphorylation of H2AX histone variant. Hydroxyurea (HU) 
was used as positive control. (Panel B) Quantification of the immunoblot shown in panel A. The 
experiment is representative of at least three experiments giving analogous results. Band 
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Figure 2.6. (Panel A) Top 10 siRNAs treatment increases AAV transduction in HeLa cells. 
Immunofluorescence images show AAV2-DsRed infection (red color) after silencing. Cells were 
silenced for 48 h and then  infected for 24 h, using an moi of 2500 vg/cell. (Panel B) The 
immunofluorescence shows that, at a different extent, six out of the top 5 siRNAs are able to trigger 
the phosphorylation of H2AX histone variant; the  nuclear ɣ-H2AX foci are visible in green. 
 
 
These results raised the possibility that it was the recognition of DNA damage, 
induced by top-10 siRNAs in the screening, to activate AAV transduction.  A 
reasonable assumption was that DDR acted as a decoy for MRN or other DNA 
damage recognition proteins, or that even ɣ-H2AX itself could be involved in 
determining AAV permissivity. 
To address these possibilities experimentally,  we devised an experimental 
strategy exploiting short DNA oligonucleotides that could act as decoys for the 
DDR response proteins and activate H2AX histone phosphorylation. The rationale 
of this approach was based on the demonstration that small DNA oligonucleotides 
transfected into the cells could mimic DNA double-strand breaks and thus act by 
acting a decoys for the DDR proteins.  A similar approach was successfully used to 
inhibit DNA repair in cancer cells and to increase the efficacy of chemotherapy in 
colorectal cancer (Quanz et al., 2009).  





















siSETD8 siCASP8AP2 siSOX15 siTROAP siNPAT
control siSETD8 siCASP8AP2 siSOX15 siTROAP siNPAT
siPHC3 siCAF-1 siSF3B1 siRTBDN siBOMB
A
B
	   53 
5’ overhang conformation and also included a ssDNA oligonucleotide, capable of 




Figure 2.7 DNA decoys. Types of DNA oligonucleotides designed to mimic a double-stranded DNA 
break. We generated oligonucleotides of 20, 30, 50,  60 base pairs, oligonucleotides ending with 5’ 




Twenty four hours after transfection of the different type of oligonucleotides we 
analyzed phosphorylation of ϒ-H2AX by immunofluorescence staining in HeLa 
cells. Only oligos having a length longer than 30 bp were able to induce nuclear ϒ-
H2AX foci.  
We decided to compare the effects produced by the synthetic oligonucleotides 
with those elicited by the siRNA against SETD8, the most effective inducer of 
permissivity to AAV transduction in our primary screening. SETD8 silencing lead to 
activation, this confirmed the data that we previously observed by 
immunoblotting (Figure 2.8). We observed that the transfection of 30, 50 and 60 
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base pairs oligonucleotides were able to induce H2AX activation, and hence a DDR 




Figure 2.8  Nuclear foci after oligonucleotide treatment. HeLa cells were transfected with double 
stranded DNA oligonucleotides. Immunofluorescence shows che appearance of nuclear foci in the 
cells treated with oligos longer than 20 bp. The siRNA against SETD8 is here used as a positive 
control.  
 
Then we assessed whether the oligonucleotides activated AAV transduction. 
Contrary to our expectations, analysis of transduction of the oligonucleotide-
treated cells with either AAV2-EGFP or AAV2-Luciferase, using an moi of 2500 
vg/cell, revealed that none of the transfected oligonucleotides was able to 
increase levels of marker transgene expression above untreated infected control 
(Figure 2.9) (Figure 2.10).    
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Figure 2.9 Oligonucleotide transfection has no effect on AAV transduction. HeLa cells were 
transfected with oligonucleotides that differ in length and end conformation for 24 h and then 
infected with AAV2-luc for 24 h. Luciferase activity has been used to measure AAV infectivity. All 
samples were normalized over untreated cells (control). Differences of siRNAs treated samples vs 
NT siRNA and oligos treated samples vs pcDNA3.1 treated cells were analyzed by one-way ANOVA 




Figure 2.10 (Panel A) Oligonucleotide transfection determines formation of ɣ-H2AX DNA foci 
without increasing AAV infection. HeLA cells were transfected with a 50 bp oligonucleotide for 24 h 
and then infected with AAV-EGFP for 24 h. The immunofluorescence panel shows that the 
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percentage of GFP-positive cells is comparable between the oligo-treated cells and the control. 
SETD8 silencing was used as positive control.  (Panel B-C) Quantification of the results of three 
different 96 well-plate replicates (mean ± sem) showing nuclear foci (C) and AAV infection (B).  
Differences of treated samples vs control were assessed by ANOVA test followed by Tukey post-hoc 





2.3 Correlation between rAAV infection and cellular checkpoint 
activation 
 
Considering that formation of ɣ-H2AX foci does not positively correlate with AAV 
infection, we decided to evaluate in more details the actual relationship between 
the downstream level of the DDR response and AAV transduction.  
It is well recognized that the phosphorylation of NBS1 serine 343 is a marker of 
DNA damage, specifically indicating the activation of the MRN complex, one of the 
earliest respondents to DNA DBSs. This activation initiates a cell-cycle checkpoint 
signaling cascades through the phosphorylation of ATM and ATR, which in turn 
also represent master sensors of DNA damage. The cellular kinases Chk1 and Chk2 
are the downstream effectors of this signaling pathway, activated through 
phosphorylation by ATM and ATR (Chaturvedi et al., 1999) (Walworth and 
Bernards, 1996). 
We therefore analyzed phosphorylation of ATM, ATR, NBS1, Chk1 and Chk2 
proteins following treatment of HeLa cells with the different oligonucleotide 
decoys (Figure 2.11). Again, results from immunoblots showed that only SETD8 
knockdown was able to activate proteins involved at different levels in the DNA 
DSB repair pathway. Oligonucleotide decoys were only able to trigger the 
phosphorylation of H2AX (Figure 2.11). We confirmed these data also by confocal 
microscopy analysis, by which we observed the formation of p-NBS1 foci only after 
SETD8 knockdown or hydroxyurea treatment, but not treatment with the 
oligonucleotides (Figure 2.12). 
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Figure 2.11 (Panel A) Immunoblotting analysis showing the activation of p-NBS1, p-ATM and p-
Chk1 in HeLa cells following transfection of DNA oligonucleotides decoys or SETD8 and Casp gene  
silencing.  The immunoblotting results show that only the SETD8  knockdown was able to induce 
the phosphorylation of ATM, NBS1 and Chk1. Chk1 phosphorylation was also induced by the Casp 
knock-down  (Panel B) Cartoon representing the DNA DBS signaling response pathway. 
 
 
Figure 2.12 Confocal microscopy of p-NBS1 foci. HeLa cells were transfected with a 50-bp 
oligonucleotide for 24 h or silenced with SETD8 siRNAs for 48 h or treatment with HU overnight. 
HeLa cells were stained with anti p-NBS1ser(343) antibody. The images show that only HU 
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2.4 Effect of the top 10 siRNAs from the AAV screening on cellular 
checkpoint activation 
 
From the results described above, it is evident that the synthetic oligonucleotides 
tested, although recognized as DNA damage, are not able to trigger the DDR 
signaling cascade, and that the sole activation of γ-H2AX is not sufficient to 
enhance cell permissivity to AAV vector transduction.  
On the other hand, the downregulation of SETD8, which produces a strong effect 
on AAV transduction, appeared not only to trigger the phosphorylation of γ-H2AX, 
but also of NBS1, ATM and Chk1 (Figure 2.11).  
 
Figure 2.13 Immunoblot showing the effect of the top 10 siRNAs on cellular DSB checkpoint 
activation. The analysis reveals that six out of ten siRNAs were able to trigger the phosphorylation 
of Chk1 (SETD8, CASP, NPAT, RTBDN, BOMB, CAF-1). The western blot also shows that changes in 
the total amount of the non-phosphorylated proteins were negligible. SETD8 and CASP82AP2 
silencing lead to a strong activation of the DNA DBS repair pathway. The two most effective siRNAs  
from the AAV transduction screening triggered he phosphorylation of ATM (Panel A), NBS1 and 
Chk1 (Panel B) respectively. Lysates of HU treated cells were used as positive controls. 
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six of them (SETD8, CASP8AP2, NPAT, CAF-1, BOMB and RTBDN) induced a 
remarkable aberration of the cell cycle profile and phosphorylation of Chk-1, 
indicating the activation of a cell cycle checkpoint. In addition to what was 
observed with the siRNA against SETD8, silencing of CASP8AP2 also induced the 
phosphorylation of NBS1 and ATM (Figure 2.13). Taken together, these results 
indicate that ,mimicking the induction of DNA damage on its own is not sufficient 
to induce permissivity to AAV transduction. Instead, the phosphorylation of Chk1, 
one of the downstream effectors of the DDR signaling cascade, following cell 
treatment with the top-10 siRNAs, appears to be a common signature that 
correlates with enhanced AAV transduction. 
 
 
Summary Results I 
 
The results described in this Chapter show that the down-regulation of all the top-
10 siRNAs that increase AAV transduction, identified in the high-throughput 
screening, was also able to increase, at different extents, phosphorylation of γ-
H2AX (a hallmark of cellular DNA damage), with siRNAs against SETD8, CASP8AP2 
and BOMB being the most effective.On the other hand, we observed that although 
the transfection of short DNA oligonucleotides in HeLa cells can efficiently mimics 
a cellular DDR response with induction of γ-H2AX histone phosphorylation to 
levels comparable to those exerted by most of the top-10 siRNAs, this was not 
sufficient to increase AAV infection. Indeed, we demonstrated that the sole 
synthetic oligonucleotide treatment was not able to trigger a complete DDR 
signaling cascade. Contrary, the down-regulation of SETD8, the most potent siRNA 
at inducing AAV transduction, appeared not only to cause phosphorylation of γ-
H2AX, but also of NBS1, ATM and Chk1. The phosphorylation of Chk1, one of the 
downstream effectors of the DDR signaling cascade, following cell treatment with 
the top 10 siRNAs, appears to be the prevalent, although not indispensable, 
common signature that correlates with enhanced AAV transduction. 
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3. Results II 
 
 
The second part of the work is focused on the identification and characterization 
of cellular factors required for efficient AAV transduction. The screening identified 
535 siRNAs that decreased AAV infection without affecting cell viability, thus 
targeting factors that positively regulate AAV transduction. These siRNAs were re-
screened for their efficiency to also increase transduction of self-complementary 
AAV (scAAV) vectors, with the ultimate goal of detecting cellular proteins 
differentially involved in the processing of the AAV ssDNA or dsDNA genomes. This 
screening was performed by simultaneously infecting cells, treated with the 535 
siRNAs, with a standard ssAAV2 expressing Ds-Red and a scAAV2 expressing EGFP. 
The results of this screening are shown in Figure 3.1. 
 
Figure 3.1. Results of the screening of 535 siRNAs previously found to decrease ssAAV2 
transduction on the simultaneous infection of HeLa cells with ssAAV2-DsRed and scAAV2-GFP. The 
siRNA against Eri1 was one of the most effective in selectively impairing ssAAV (almost 20-fold 
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3.1 Cellular factors selectively required for ssAAV infection.  
 
We concentrated our attention on 7 factors (Table 2). The siRNAs against 4 of 
these selectively impaired ssAAV but not scAAV transduction. The targeted factors 
were C6ORF146, of unknown function; the exoribonuclease Eri1, involved in the 
regulation of the histone dosage and degradation of endogenous microRNAs 
(details shown in Figure 3.1); RDBP, a factor implicated in the RNA metabolism; 
and SCGB1D1, a factor predicted to be secreted. Other 3 factors instead appeared 
required for both ssAAV and scAAV transduction. These were BCCIP, a protein 
involved in DNA repair and interacting with BRCA2 and p21; MSH5, a protein 
acting in the DNA HR pathway; and PIK4CA, a cytoplasmic kinase.  
 
Table 2. Factors required for cell permissivity to AAV transduction. The 7 factors listed were all 
identified in a primary screening testing AAV2-luciferase transduction of HeLa cells (the fold 
reduction in luciferase activity compared to control is reported in the first column). Short 
interfering RNAs against the 7 factors were then used in a secondary screening simultaneously 
assessing transduction with ssAAV2-DsRed and scAAV2-GFP (results in columns 2 and 3 
respectively); siRNAs against the factors boxed in green selectively impaired ssAAV, those against 
the factors boxed in orange both ssAAV and scAAV. 
 
 
 We rescreened the selected siRNAs in cultured cell lines derived from different 
histological type of cancers, including as HeLa (cervical cancer), Huh7 
(epatocarcinoma), U2OS (osteosarcoma), T98G (glioblastoma). Forty-eight hours 
after siRNA administration cells were infected simultaneously with ssAAV2-DsRed 
and a scAAV2-EGFP at an moi of 2500 vg/cells. As shown in Figure 3.2, the only 
siRNAs found to selectively inhibit ssAAV but not scAAV in a consistent manner 









































Figure 3.2. Eri1 silencing leads to a selective decrease of ssAAV infection in different cell lines 
(panel A). Representative immunofluorescence images in HeLa cells showing Eri1 silencing affects 
selectively ssAAV trasduction; the cells were coinfected simultaneously with ssAAV2 ds-Red and 
scAAV EGFP using a moi of 2500 vg/cell (panel B). Results represent mean and s.e.m. from 3 
independent experiments. The percentage of infected cells was first normalized over untreated 
cells, and then we compared the ssAAV2-DsRed over the scAAV-EGFP values through t-test. Star-
code for significance: *** P<0.001, ** P<0.01, * P <0.05. 
 
                                    
 
Figure 3.3. Eri1 silencing decreases ssAAV infection without affecting cell viability in different cell 
lines. Results represent mean and s.e.m. from 3 independent experiments. No statistically 
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Interestingly, Eri1 silencing also decreased ssAAV infection in highly permissive 
cells.  Previous work from our group showed that the ATM−/− fibroblasts (AT5), a 
cell line lacking the ataxia-telangectasia mutated factor, one of the master 
regulators in the DDR pathway, are highly permissive to AAV transduction (Zentilin 
et al., 2001) . We silenced Eri1 with its specific siRNA for 48 hours in AT5 fibroblasts, 
and then we infected the cells with rAAV2-EGFP for 24 hours. The  results indicated 
that the absence of Eri1 in AT5 cells totally abolishes the high permissivity to AAV, 
suggesting that Eri1 regulates AAV infection independently from or upstream the 
DDR pathway (Figure 3.4). 
 
Figure 3.4. Representative immunofluorescence images showing that Eri1 silencing also decreases 
AAV transduction in ATM -/- fibroblasts (AT5 cells), which are highly permissive to AAV infection. 
 
The siRNA used for the Eri1 knockdown experiments is a commercial pool of 4 
individual siRNAs against the Eri1 mRNA. To exclude off-target effects, we 
deconvoluted this pool by testing the effects of the individual siRNAs separately. 
Three out of the four siRNAs composing the Eri1 silencing pool (siRNAs #1, #2, #3, 
#4 ) significantly decreased AAV-luciferase infection (Fig. 3.5A). We also tested the 
levels of the Eri1 mRNA in cells treated by the siRNA pool, and found that this was 
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Figure 3.5. siRNA deconvolution experiment.  Panel A: Three individual siRNAs out of the four 
composing the Eri1 silencing pool used in the screening ( #1, #2, #3, #4) were able to significantly 
decrease AAV infection. After normalization over control, data were compared to mock by ANOVA 
test followed by Tukey post-hoc test. 
Panel B: RT PCR analysis revealed that Eri1 siRNA was able to significantly decrease ER1 mRNA. The 
values derived from siRNA treated cells were first normalized against untreated cells (control), and 
then  compared with mock by t-test.  
Star-code for statistical significance: *** P<0.001, n.s. not significant. 
 
 
3.2 Eri1 stimulates rAAV transduction 
 
Our data indicate that Eri1 is required for efficient AAV transduction, since the 
knock down of its mRNA significantly decreased it. We thus wanted to test 
whether, on the contrary, the overexpression of the protein might increase 
transduction. To this end, we transfected a plasmid encoding recombinant Eri1 
fused to GFP under the control of the CMV promoter in different cell lines (HeLa, 
T98G, 293T, U2OS, Huh7, MRC5). Twenty-four hours after transfection cells were 
infected with AAV2-DsRed (moi, 2500 viral particles per cell). The quantification, by 
high-content fluorescence microscopy, of the percentage of GFP positive cells 
allowed measuring the number of transfected cells, whereas the count of Ds-Red 
positive cells indicated the extent of AAV infection. We observed that AAV 
transduction increased following Eri1 overexpression, from 2 up to 7 times 





































































	   66 
showing low permissitivity, such as MRC5 (Figure 3.7). 
 
Figure 3.6. Effect of Eri1 overexpression on AAV transduction in different cell lines. Results show 
mean and s.e.m. from three independent experiments. The values derived from Eri1 transfected 
cells were first normalized against untreated cells, and then we compared the results obtained in 
Eri1-GFP transfected cells with those in pcDNA3.1 transfected cells, by t-test. Star-code for statistical 
significance: *** P<0.001, ** P<0.01, * P <0.05. 
 
Figure 3.7. Representative immunofluorescence images in MRC5 cells showing AAV infection after 
Eri1-GFP overexpression. MRC5 cells were transfected with a plasmid expressing an Eri1-GFP fusion 




























































	   67 
 
Consistent with the screening results, Eri1 overexpression did not significantly 
modify the levels of scAAV transduction, confirming that this factor is crucial for 
ssAAV transduction (Figure 3.8 panel A). The enhancing effect on rAAV2 
transduction increased linearly with the amount of transfected plasmid, as shown 
for HeLa cells infected with AAV2-Luciferase reporter vector (Figure 3.8 panel B). 
The bell shaped dose-response curve is probably consequent of toxicity of the 
protein at high doses.  
 
 
Figure 3.8. Panel A : The effect of Eri1 overexpression on scAAV transduction in not significant. 
Treated samples were compared to the control using one-way ANOVA followed by Tukey post-hoc 
test; N.s. = not significant . Panel B : the graph shows a dose response curve that correlates 
transfected Eri1 DNA and ssAAV transduction efficiency in HeLa cells. Results show mean and s.e.m. 
from three independent experiments. The infection of ssAAV2 of transfected cells was first 
normalized against control; then we compared the Eri1-GFP transfected cells over the pcDNA3.1 
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3.3 Mechanism of action of Eri1 on AAV transduction 
 
3.3.1 Eri1 levels do not correlate with the amount of AAV DNA inside 
the cell nucleus. 
 
Eri1 is an evolutionarily conserved 3’-5’ exoribonuclease, which participates in end-
processing and turnover of replication-dependent histone mRNAs (Dominski et al., 
2003). Over the course of evolution, Eri1 has also been recruited into a variety of 
conserved and species-specific regulatory small RNA pathways, which include the 
regulation of endogenous small RNAs (Kennedy et al., 2004). Eri1, as other stem-
loop binding proteins, localizes predominantly in the nucleus at the G1/G2 phases 
and at the beginning of S phase of the cell cycle. Throughout the S phase, Eri1 is 
partially redistributes to the cytoplasm. Binding to histone mRNA is necessary for 
cytoplasmic localization (Yang et al., 2006). Since Eri1 shuttles between the 
nucleus and the cytoplasm, we wanted to verify whether Eri1 silencing or 
overexpression could somehow interfere with AAV nuclear entry. We performed 
experiments either silencing Eri1 for 48 hours or overexpressing the protein for 24 
hours. After treatment, the cells were infected for 24 hours with AAV2-Luc, using a 
moi of 2500 vg/cell. We quantified, by real time PCR, the number of rAAV genomes 
present in the HeLa nuclear fraction in order to measure the extent of viral DNA 
nuclear entry. Eri1 levels did not correlate with the amount of AAV DNA inside the 
cell nucleus (Figure 3.9). 
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Figure 3.9. Efficiency of AAV transduction (panel A) and amount of viral DNA in the nucleus (panel 
B) in HeLa cells in which Eri1 was either knocked out or overexpressed. Results show mean and 
s.e.m. from three independent experiments. Statistical significance was assessed by t-test 




3.3.2 The effect of Eri1on ssAAV transduction is independent from the 
RNAi pathway. 
 
It has also been demonstrated that Eri1 physically interacts and cooperates with 
the Dicer complex for miRNA precursor processing (Kennedy et al., 2004). Thus we 
wanted to ascertain whether the effect of the protein on AAV transduction were 
mediated by interference with the miRNA pathway. We knocked out Dicer and 
Drosha in HeLa cells by specific siRNA transfection; after 48 hours, cells were 
infected with AAV-luc, at a moi=2500 vg/cell (Figure 3.10). Changes in AAV 
infection after Drosha silencing were negligible, while the Dicer knock-down 
exhibited an opposite effect on AAV transduction compared to treatment with the 
Eri1 siRNA. These data suggest that Eri1 does not exert its effect on the modulation 
of AAV transduction through the RNAi pathway.  
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Figure 3.10. Effect of Dicer and Drosha knockout on AAV transduction. HeLa cells were silenced for 
48 hours using siRNAs against Dicer or Drosha and then infected with AAC-luc. The mean ± sem of 
three independent experiments is shown. Differences between siRNAs treated samples over the 
control were assessed by using one-way ANOVA test followed by Tukey post-hoc test. Code for 




3.3.3 Eri1 mutants 
 
To start exploring the molecular mechanisms by which Eri1 selectively favours 
ssAAV transduction, we took advantage of three Eri1 mutants, each one lacking a 
specific functional domain of the protein (kindly provided by Dr. Zbigniew 
Dominski (Yang et al., 2006)). These Eri1 variants include: a mutant deleted in the 
SAP domain, the putative Eri1 DNA binding domain, useful to assess a possible 
direct interaction of Eri1 with the ssAAV DNA genome; a mutant in R105A, unable 
to bind the stem loop structure typical of the histone mRNAs, useful to prove a 
possible involvement of the histone mRNA degradation pathway during the ssAAV 
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to degrade both histone mRNA and endogenous small RNAs (Figure 3.11).  
 
 
Figure 3.11 Eri1 mutants. In order to understand the molecular mechanism by which Eri1 
selectively favors ssAAV transduction, we took advantage of Eri1 mutants lacking the DNA putative 
binding domain (ΔSAP), the histone mRNA-binding domains (R105A), or mutated in the catalytic 
domain of the protein (M235A).  
 
We sub-cloned the Eri1 mutant cDNAs into a N-terminal P-Flag CMV mammalian 
expression vector to perform protein overexpression experiments and protein 
functional assays.  
We transfected the three Eri1 mutants in HeLa cells and verified their expression by 
western blotting (Figure 3.12).  
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Figure 3.12. Levels of expression of Eri1 mutants. HeLa cells were simultaneously transfected with 
expression plasmids for the Eri1 mutants and the p-EGFP N1 plasmid (10:1 ratio). Western blot 
analysis was performed with an anti-Flag antibody. HSC70 was used as loading control and an anti-
GFP antibody as transfection control. 
 
The mutant Eri1 expression vectors were transfected in HeLa and, after 24 hours, 
cells were infected with AAV2-luc, moi 2500 vg/cell, in order to achieve a 
quantitative measurement of AAV infectivity. As shown in Figure 3.13 panel A, 
only the wild-type Eri1 was able to induce AAV infection. 
Eri1 was described as a factor able to degrade several histone mRNAs; more 
specifically it was deeply characterized as an exoribonuclease capable to strongly 
reduce the mRNA of the H2A histone. We therefore assessed the ability of the Eri1 
mutants to degrade the H2A mRNA. After 24 hours from transfection, the levels of 
H2A mRNA were determined by real-time PCR. Our results indicate that all the 
mutants, at a different extent, were less efficient in histone mRNA degradation 
compared to wild-type Eri1 (Figure 3.13 panel B). Taking into account the intrinsic 
difficulty to study histone gene expression, due to their huge number, their 
temporal tight regulation, considering also possible biases coming from the 
cellular model we used,  we decided to focus on HIST1 H2A gene expression; 
despite this, other results indicate us that wild-type Eri1 overexpression is able to 
reduce significantly also HIST1 H3A and HIST1H4A histone mRNAs (data not 
shown). Since HU treatment has been previously described as an agent able to 
lead to cellular histone mRNA degradation (Sittman et al., 1983) we used this drug 
as a positive control in both AAV infection experiments and histone mRNA 
analysis. Comparing the results from the mutant overexpression experiments, we 
observed that there was a general negative correlation between AAV transduction 
and  histone mRNA levels (Figure 3.12). This observation suggested that Eri1 
could modulate AAV infection by altering histone dosage, possibly modulating the 
chromatinization of the recombinant AAV genomes.  
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Figure 3.13. Eri1 mutants were overexpressed in HeLa cells for 24 hours before infection with an 
AAV2 expressing the firefly luciferase reporter gene using an moi of 2500 vg/cell. Panel A shows the 
levels of histone H2A mRNA normalized over untreated control;  Eri1 mutants are not able to 
reduce H2A mRNA. Panel B shows the effect on AAV transduction of Eri1 mutants compared to wild 
type protein, measured as luciferase activity. Statistical significance was computed comparing 
treated samples over mock (Panel A) or wild type Eri1 (Panel B) using one-way ANOVA test followed 
by Tukey post-hoc test. The graphs show mean ± s.e.m. of three different experiments. Code for 
statistical significance: ** P=0.01, *** P=0.001, n.s. not significant. 
 
 
3.3.4 Hydroxyurea requires Eri1 to increase ssAAV transduction 
 
Hydroxyurea, a drug markedly increasing AAV transduction, also triggers the 
degradation of several classes of histone mRNAs through a molecular mechanism 
that is not completely understood yet (Sittman et al., 1983). To verify whether HU 
requires Eri1 activity to promote the enhancement of AAV transduction, we 
silenced Eri1 in HeLa cells before HU treatment and AAV2-Luc infection (see 
Figure 3.14 panel A for a scheme of the experiment). As expected, HU treatment 
alone was able to increase AAV transduction but, notably, this effect was totally 
abolished if Eri1 was down-regulated (Figure 3.14 panel B). Thus, HU requires the 
integrity of Eri1 to exert its effect on ssAAV transduction.  By RT-PCR analysis, we 
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(Figure 3.15). Although there are many possible and described mechanisms that 
can explain the ability of HU to increase rAAV transduction, (e.g. augmented AAV 
nuclear entry, increased AAV double strand DNA conversion (Russell et al., 1995) 
(Johnson and Samulski, 2009) our observations underline the existence of an 
additional effect of HU that requires Eri1 catalytic activity.  
 
Figure 3.14. Combined effect of Eri1 knockdown and HU treatment on AAV infection of HeLa cells. 
Scheme of the experiment (panel A): Eri1 was silenced in HeLa cells before HU treatment; cells were 
been infected using an AAV2 vector expressing the firefly luciferase reporter gene. HU treatment 
alone was able to increase AAV infection and this effect was totally abolished when Eri1 was down-
regulated (panel B). The results show mean±s.e.m. of 3 independent experiments, differences, 
between samples and control were evaluated by one-way anova followed by Tukey post-hoc test. 
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Figure 3.15. Levels of Eri1 mRNA in HeLa cells treated with HU. HeLa cells were treated with HU for 
8 hours. The results are normalized over HPRT expression and show mean±s.e.m. of at least 3 
independent experiments. Difference between HU treated sample and control were assessed by t-
tests.  Code for statistical significance (t-test) :* P<0.05. 
 
3.3.5 rAAV chromatinization affects viral transduction 
 
Although previous works have demonstrated that episomal rAAV genomes are 
assembled in a chromatin-like structures, the mechanism by which 
chromatinization occurs on AAV genomes is not elucidated (Marcus-Sekura and 
Carter, 1983) (Penaud-Budloo et al., 2008). Some authors previously reported that 
AAV genomes, once inside the nucleus of the target cells, are covered by histones, 
and that HDAC inhibitors could enhance the efficiency of AAV transduction (Okada 
et al., 2006). With the ultimate goal of studying the impact of AAV genome 
chromatinization in the establishment of successful viral transduction, we 
analyzed our primary siRNA screening data as far the HDAC genes were specifically 
concerned. We observed that, following down-regulation of all the six HDAC 
proteins, In all cases, AAV transduction increased from 2 up to 15 folds compared 
to the control (Figure 3.16). These observations further underline the correlation  
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Figure 3.16. Levels of AAV transduction after HDAC knock down. HeLa cells were silenced for 48 
hours and then infected with ssAAV2-luc for 24 hours. The measurement of firefly activity has been 
use to assess AAV infectivity and then the values were normalized over Nt-siRNA control. Bars 




To further explore this issue, we reconsidered the effect of the siRNA against CAF-
1, one of the top-10 siRNAs increasing AAV transduction selected in the high 
throughput screening. CAF-1 is described as the main replication-dependent 
chromatin assembly factor in eukaryotic cells (Marheineke and Krude, 1998). We 
observed that its down-regulation in HeLa cells increased ssAAV transduction over 
15 folds compared to control (Figure 3.17). However, when we co-silenced 
simultaneously Eri1 and CAF-1 the positive effect of CAF-1 siRNA on AAV infection 
was totally abolished (Figure 3.18). These results are consistent with the 
possibility that CAF-1 might participate in chromatin assembly during the 
processing of the ssAAV genome to a transcription competent ds molecule and, 
importantly, emphasizes the notion that rAAV chromatinization could be 
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Figure 3.17. Effect of CAF-1 knock down on AAV transduction. HeLa cells were silenced for 48 
hours using Eri1 and CAF-1 siRNAs. Shown are the mean±s.e.m. of 3 independent experiments. 
Differences, between siRNA treated samples and control were evaluated by one-way ANOVA 
analysis followed by Tukey post-hoc test. Code for statistical significance: *** P<0.001, n.s= not 
significant.. 
 
Figure 3.18. Effect of the simultaneous knock down of Eri1 and CAF-1 on AAV transduction. Eri1 
and CAF-1 were simultaneously silenced in HeLa cells. After the knock-down, cells were infected 
with AAV2-EGFP. Differences between siRNA treated samples and control were evaluated by using 
one-way ANOVA test followed by post-hoc test. Graphs show the mean±s.e.m. of 3 independent 
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3.3.6 ssAAV and scAAV chromatin immunoprecipitation after Eri1 
overexpression or HU treatment   
 
To directly assess the molecular interaction of histone proteins with AAV genomes, 
we performed chromatin immunoprecipitation (ChIP) studies using specific 
antibodies to histone H3 and H4, as well as to the variant H3.3, considered a mark 
of open-chromatin (Chow et al., 2005) and pan acetylated H3 (Ac-H3), commonly 
associated with transcriptional activity (Cheung et al., 2000). We also performed 
ChiP experiments using antibodies against some DDR-related proteins (MRE11 and 
NBS1), inhibitory on AAV transduction (Cervelli et al.) (Lovric et al.), against H2AX, a 
DNA-damage related histone variant (Kuo and Yang, 2008) and against CAF-1 in 
order to asses its association with the AAV genomes. 
Cross-linked and sonicated chromatin from untreated HEK293T and from cells 
infected simultaneously with ssAAV2-DsRed and scAAV2-EGFP at a moi of 1x104  
viral particles per cell, with or without Eri1 overexpression or HU treatment, was 
immunoprecipitated with each antibody. The amount of cross-linked DNA 
specific for rAAV was then assessed by real-time PCR using specific primers 
for ssAAV2-DsRed and scAAV2-EGFP genomes. 
The overexpression of Eri1 determined an over 10-fold, selective reduction of 
ssAAV genome association with H3 and H4 proteins, while changes were 
negligible for scAAV AAV. After Eri1 overexpression or HU treatments, we also 
measured a decreased of H3 trimethyl K9 association with the AAV genome, a 
histone mark related to transcriptional repression. Moreover, we observed a 
different chromatin composition pattern on the self-complementary AAV genome, 
which showed enrichment for the histone variant H3.3 compared to ssAAV (Figure 
3.19). Since H3.3 is mark of open-chromatin and it can be loaded onto DNA in a 
replication-independent manner, this could explain its presence on the scAAV 
genome. Increase of ssAAV2 transduction by Eri1 overexpression also caused a 
significant decrease in the association, with the viral DNA, of proteins of the 
cellular DNA damage response, such as NBS1 and MRE11.  
After these treatments, we also measured a decrease in the association with the 
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AAV genome of some molecular signatures typical of the DDR, such as 
phosphorylated histone H2AX Eri1 overexpression or HU treatment also lead to a 
decrease of CAF-1 associated with the ssAAV genome (Figure 3.19).  
Taken together, these results suggest that Eri1 regulates rAAV transduction 
through cellular histone dosage modulation and, in particular, that it increases cell 
permissivity to ssAAV transduction by relieving the inhibition that 
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Figure 3.19. Results of chromatin immunoprecipitation experiments. ChIP experiments showed 
that the overexpression of Eri1 or HU treatment determined an over 10-fold, selective reduction of 
ssAAV genome association with H3 and H4 (panel A), while changes were negligible for scAAV DNA 
and for selected cellular genes (panel B). A different chromatin composition pattern was observed 
on the self-complementary AAV genome, which was enriched in the histone variant H3.3 compared 
to ssAAV (panel B). Eri1 overexpression, similar to HU treatment, increased AAV association with 
acetylated H3 and decreased that with H3 tri-methyl K9; a reduction in the DNA-damage related 
markers p-H2AX and NBS1 was also noticed. Differences between Eri1 or HU treated samples and 
control were assessed by using one-way ANOVA followed by Tukeys post-hoc test. Results 
represent the mean and s.e.m. from at least three independent chromatin immunoprecipitation 
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Summary Results II 
 
The findings obtained in this chapter allowed shedding light on cellular factors 
involved in single-stranded (ss) AAV genome processing.   
Starting from the data of high-throughput screening on AAV transduction we 
compared the effect of individual siRNAs against approximately 1,500 genes on 
transduction of HeLa cells with a standard, ssAAV2 vector expressing the Ds-Red 
monomer and a self-complementary (sc) AAV2 vectors expressing EGFP 
respectively. Notably, this analysis highlighted a previously unrecognized essential 
and selective role of ERI-1, a 3'-exoribonuclease known to degrade endogenous 
miRNAs and histone mRNAs, for ssAAV transduction. To understand the molecular 
mechanism by which ERI-1 selectively favors ssAAV transduction, we took 
advantage of ERI-1 mutants lacking the DNA- or the histone mRNA-binding 
domains, or mutated in the catalytic domain of the protein. We determined that 
ERI-1 affects ssAAV transduction neither via degradation of endogenous 
microRNAs nor by direct interaction with the AAV genome. In contrast, we 
observed that AAV transduction negatively correlated with histone mRNA levels. 
Interestingly, hydroxyurea, a drug markedly increasing AAV transduction, also 
determined histone mRNA degradation and required integrity of ERI-1 for its effect 
on AAV.  By chromatin immunoprecipitation studies aimed at assessing the extent 
of chromatinization of the AAV genome, we concluded that the overexpression of 
ERI-1 determined an over 10-fold, selective reduction on ssAAV genome 
association with H3 and H4, while changes were negligible for scAAV DNA and for 
selected cellular genes. Consistent with chromatin exerting a repressive role on 
ssAAV transduction, we also observed that the downregulation of the main 
replication-dependent histone chaperone CAF-1 induced an over 20-fold increase 
in transduction. In line with our previous findings, we noticed that increase of 
ssAAV2 transduction by ERI-1 overexpression also caused a significant decrease in 
the association, with the viral DNA, of proteins of the cellular DNA damage 
response (DDR; e.g. Nbs1 and Mre11). 




This PhD thesis aims to characterize some molecular mechanisms involved in the 
cellular regulation of rAAV transduction. Starting from the data obtained from a 
high-throughput screening on rAAV transduction, performed using a genome-
wide siRNA library, here we characterize the effect of some cellular factors involved 
in rAAV infection. In particular, we demonstrate that the activation of a cellular S-
phase checkpoint is the prevalent common signature of the top-10 siRNA able to 
increase AAV transduction. This is in line with our previous observations that the 
activation of DNA damage response correlates with the efficiency of AAV in vitro.   
The second part of this thesis highlights a previously undervalued role of the AAV 
genome chromatin state as a determinant of cellular permissivity to transduction. 
In particular, we describe and discuss the action of Eri1, a cellular exoribonuclease 
that modulate rAAV transduction exerting its role through the regulation of the 
cellular histone dosage. 
A unifying hypothesis that links DNA damage and S-phase checkpoint activation 
with the rAAV chromatinization process is presented in the model described at the 
end of this discussion section. 
 
 
4.1 The activation of cellular S-phase checkpoint positively 
correlates with AAV transduction 
 
Long standing evidence indicates that AAV genome can be recognized inside the 
host cell by the DNA damage response (DDR) machinery and that genotoxic 
damage increases cellular permissivity to AAV (Zentilin et al., 2001) (Russell et al., 
1995). In addition, different laboratories, including our own, have previously 
shown that proteins of the DDR, namely those of the MRN (MRE11-RAD50-NBS1) 
complex, inhibit AAV transduction in both cell culture (Cervelli et al., 2008) and 
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primary cells in vivo (Lovric et al., 2012). To systematically identify the host cell 
factors involved in the internalization, intracellular trafficking, processing of AAV 
genome and, eventually, AAV gene expression, either positively or negatively, we 
performed a high-throughput screening using a genome-wide siRNA library 
(18175 human gene targets). Consistent with our previous results, among the 
genes that restrict transduction by AAV vectors, this genome-wide screening, 
identified members of the MRN complex and other genes involved in the cellular 
DDR, as well as genes belonging to the ubiquitin-proteasome system.  
Following these findings, we decided to investigate whether the top ten siRNAs of 
our primary screening were able to induce cellular DNA damage in the absence of 
viral infection. We first analyzed the phosphorylation of histone H2AX at Serine 
139 (γ-H2AX), a hallmark of cellular DNA damage (Kuo and Yang, 2008), in HeLa 
cells treated with the selected siRNAs. The down-regulation of all the top-10 genes 
was able to increases γ-H2AX phosphorylation at different extents, with SETD8, 
CASP8AP2 and BOMB being the most effective. To further understand the 
contribution of DNA damage on rAAV transduction efficiency, we devised an 
experimental strategy exploiting short DNA oligonucleotides as decoys of the DDR 
response proteins, inhibitory of rAAV transduction. The rationale of this approach 
was based on the demonstration that small DNA oligonucleotides transfected into 
cells mimic DNA double-strand breaks and acted by disorganizing the damage 
signaling and DNA repair machinery. A similar approach was successfully used to 
inhibit the DNA repair system in cancer cells and to increase the efficacy of 
chemotherapy in colon or rectal cancer (Quanz et al., 2009). All the transfected 
oligonucleotides were able to promote phosphorylation of γ-H2AX histone in HeLa 
cells comparably to the effect exerted by most of the top-10 siRNAs; however, 
contrary to the top-10 siRNAs or genotoxic agents such as hydroxyurea, the 
oligonucleotide treatment was unable to increase AAV transduction. We showed 
that the synthetic oligonucleotides tested, although recognized as damaged DNA, 
were not able to trigger completely the DDR signaling cascade, and that the sole 
activation of γ-H2AX was not sufficient to enhance cell permissivity to AAV vector 
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transduction. On the other hand, the down-regulation of SETD8, the most potent 
siRNA at inducing AAV transduction, appeared not only to cause phosphorylation 
of γ-H2AX, but also of NBS1, ATM and Chk1. Further analysis, using all top 10 
siRNA, revealed that at least 6 of them (SETD8, CASP8AP2, NPAT, CAF-1, BOMB and 
RTBDN) induced a remarkable aberration of the cell cycle profile and 
phosphorylation of Chk-1, a marker that indicates the activation of a cell cycle 
checkpoint (Martinho et al., 1998). We demonstrated that induction of DNA 
damage in terms of γ-H2AX activation on its own is not sufficient to explain the 
molecular mechanism of the siRNAs action. On the other hand, the 
phosphorylation of Chk1, one of the downstream effectors of the DDR signaling 
cascade, following cell treatment with the top 10 siRNAs, appears to be the 
prevalent, although not indispensable, common signature that correlates with 
enhanced AAV transduction. Taken together, these results indicate that several of 
the siRNAs inducing cellular permissivity to AAV do so by inducing DNA damage 
and checkpoint activation.  
 
 
4.2 Eri1 selectively favours ssAAV transduction 
 
The results of the high throughput screening allowed us to identifying not only 
siRNAs that enhanced but also 535 siRNAs that decreased AAV transduction 
without affecting cell viability. The targets of these siRNAs apparently comprise 
factors that are required for AAV transduction. Considering that the single-strand 
to double-strand conversion of the AAV vector genome inside the host cell 
potentially represents a limiting step for a successful gene transfer, we decided to 
specifically focus our study on factors involved in AAV genome processing. With 
this concept in mind, we compared, in secondary screenings, the effect of 
individual siRNAs against the approximately 500 genes required for AAV infection, 
on the transduction efficiency of a standard ssAAV2 vector expressing the Ds-Red 
monomer and a scAAV2 vectors expressing EGFP. Among other genes, the results 
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of our screening revealed that Eri1, a 3’-exoribonuclease known to degrade 
endogenous miRNAs and histone mRNAs (Kennedy et al., 2004) (Yang et al., 2006), 
was essential for ssAAV, but largely dispensable for scAAV transduction. The 
knockdown of Eri1 decreased ssAAV infection about 5 fold over control whereas 
changes in the scAAV transduction were negligible.  
Eri1 is required for replication-dependent degradation of histone mRNA, but it is 
also involved in microRNA homeostasis and maturation of ribosomal 5.8S RNA 
(Gabel and Ruvkun, 2008; Thomas et al., 2012). To discriminate the exact molecular 
mechanism by which Eri1 selectively favours ssAAV transduction, we took 
advantage of Eri1 mutants lacking the DNA- or the histone mRNA-binding 
domains, or mutated in the catalytic domain of the protein. Our analysis clearly 
determined that Eri1 does not affect ssAAV transduction via degradation of 
endogenous microRNAs, nor by direct interaction with the AAV genome, since the 
overexpression of mutants lacking the putative DNA-binding domains ( ΔSAP ), or 
mutated in the catalytic domain ( M235A ) of the protein were not able to induce 
AAV transduction. In contrast, we observed that a defect in the histone mRNA 
degradation activity of Eri1 negatively correlates with AAV transduction. Taken 
together, these data suggest that Eri1 may exert its action on AAV transduction 
through the modulation of the cellular histone dosage and consequently 
influencing the dynamics of chromatin remodeling on AAV genome.  
 
 
4.3 rAAV chromatinization influences viral transduction 
 
It is not a novelty that chromatin dynamics and epigenetic modifications play a 
pivotal role in the biology of many viruses. Both AAV and another parvovirus, MVM 
(Minute Virus of Mice), have been previously described as organized in a chromatin 
structure within hours after infection in cell culture (Ben-Asher et al., 1982) 
(Marcus-Sekura and Carter, 1983). Moreover, R.O. Snyder and colleagues 
demonstrated, in non -human primates, that rAAV vectors reside predominantly as 
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episomal monomeric and concatameric circles in transduced skeletal muscle and 
that episomal AAV genomes assimilate into chromatin with a typical nucleosomal 
pattern (Penaud-Budloo et al., 2008).  The same laboratory also found that vector 
genomes and gene expression persist for years in quiescent tissues, such as 
muscle, and suggested that the chromatin structure of AAV DNA was important for 
episomal maintenance and transgene expression (Penaud-Budloo et al., 2008).   
In this respect, from an analysis of the data of the high-throughput screening, it is 
interesting to note that all the siRNAs directed against cellular histone 
deacetylases (HDACs) enhanced AAV transduction; the fact that HDACs are 
inhibitory toward AAV represents a possible indication that the chromatin state of 
the vector genome is crucial for an efficient viral transduction. The HDAC 
knockdown was able, in HeLa cells, to increase AAV infection at different extents, 
from 2.5 folds up to 15. These findings highlight the importance of chromatin 
epigenetic modifications in the efficient AAV-mediated transgene expression, and 
confirm previous data demonstrating that HDAC inhibitors enhanced rAAV 
transduction, probably by increasing the acetylation of the histones associated 
with AAV genome (Okada et al., 2006). 
 
 
4.4 Histone metabolism and AAV infection 
 
Eri1 plays a pivotal role in the modulation of histone metabolism; thanks to its 
exoribonuclase activity it can trigger the specific degradation of several classes of 
histone mRNAs being able to selectively recognize a particular stem-loop structure 
present only in the 3’ of histone mRNA (Hoefig et al., 2013). Replication‐dependent 
histone transcripts are characterized by the absence of introns and by the 
presence of a stem‐loop structure at the 3′ end of a very short 3′ untranslated 
region (UTR). These features, together with a need for active translation, are a 
prerequisite for their rapid decay. It has been demonstrated that Lsm1, a factor 
belonging to the histone mRNA processing complex, cooperates with Eri1 
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exoribonuclease promoting genomic stability through the control of histone 
mRNA decay in yeast (Herrero and Moreno, 2011). Interestingly, our high-
throughput screening revealed that the silencing of both Lsm1 and Lsm7, factors 
cooperating with Eri1 to degrade histone mRNA, were able to decrease ssAAV 
infection from 3.3 to 6.7 folds compared to the control. These data provided 
another evidence supporting the concept that Eri1 modulates AAV infection 
acting through the histone mRNA degradation pathway.   
Histone biosynthesis is so tightly synchronized with DNA synthesis that pools of 
free histones are virtually absent in proliferating cells because they are synthetized 
at levels matching the actual requirement for chromatin assembly; only a little 
variation on the stoichiometric ratio between DNA and histones could be 
dramatically toxic for the cells (Osley, 1991) (Singh et al., 2010).   
Cellular histone dosage is tightly regulated at a transcriptional level. The 
regulation of the cyclin E-Cdk2 substrate NPAT, which is essential for both histone 
gene expression and S phase entry, provides a mechanism coordinating histone 
and DNA synthesis in mammalian cells (Zhao, 2004). Interestingly, the siRNA 
against NPAT, a master regulator of the histone gene transcription, is one of the 
top-10 siRNAs able to increase AAV infection identified in our screening.  
 
 
4.5 DNA damage induced by hydroxyurea requires the integrity of 
Eri1 to increase AAV transduction 
 
DNA damage induces a down-regulation of histone gene expression through the 
G1 checkpoint pathway and also triggers histone degradation at the mRNA level 
(Su et al., 2004) (Muller et al., 2007) (Levine et al., 1987). The mRNA levels of 
mammalian replication-dependent histones, both linker histone H1 and the four 
core-histones (H2a, H2b, H3, H4), are down-regulated in a coordinated manner in 
parallel with the inhibition of DNA synthesis upon DNA damage (Su et al., 2004). It 
is well established that hydroxyurea, a drug known to increase AAV transduction, 
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is also able to trigger the degradation of histone mRNAs (Hoefig et al., 2013). Taken 
together this evidence suggested us that hydroxyurea could exert its effect on 
AAV transduction by acting on the histone mRNA degradation pathway. Our 
experiments showed that HU requires, indeed, the integrity of Eri1 to exert its 
inducing effect on ssAAV transduction, since its enhancing action is totally 
abolished upon knocking down Eri1. Hydroxyurea may use different mechanisms 
to modulate AAV transduction. We previously hypothesized that HU, like other 
genotoxic treatments, contributes to divert inhibitory proteins of the DDR 
machinery away from the rAAV genomes (Cervelli et al., 2008). Samulski and 
colleagues showed that HU enhances AAV transduction also by increasing the AAV 
nucleolar trafficking (Johnson and Samulski, 2009). In the present settings, we 
observed that treatment of HeLa cells with HU caused a two fold increase of Eri1 
mRNA level suggesting an additional molecular mechanism for the positive effect 




4.6 Dynamics of cellular protein associations onto the AAV DNA 
 
The findings of the present work together with our previous results support a 
model according to which, upon entering the nucleus, recombinant ssAAV 
genomes, by virtue of both their ssDNA nature and the presence of the viral ITRs, 
are recognized by cellular DDR proteins, including MRN and MDC1. It is 
conceivable to hypothesize that the DNA damage response evoked by the 
presence of single stranded, hairpinned DNA genomes or during the conversion of 
from ss- to ds- viral DNA contributes to recruit histone types that are specific for 
closed heterochromatin, as it was recently described (Ayrapetov et al., 2014). 
Our results show that the histone chaperone CAF-1 binds the AAV genome and 
exerts a negative effect on the efficiency of transgene expression. Multiple 
published evidence indicate that CAF-1 plays a role in setting up a repressed 
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chromatin state, illustrating that the propagation of silenced chromatin is 
intimately linked to the histone deposition process. Moreover, it was shown that 
the loss of CAF-1 function causes heterochromatin abnormalities and loss of 
viability during development in mouse, Xenopus and Drosophila (Quivy et al., 
2001) (Moggs et al., 2000). It is possible that a mechanism that contributes to 
repress AAV transduction at a chromatin level can represent an evolutionary 
conserved innate immunity defense of the host cell against invading viruses (Lilley 
et al., 2010) (Arbuckle and Kristie, 2014). 
On the other hand, scAAV genomes, proficient for self-annealing, can skip the 
double-strand conversion process together with a chromatinization process that is 
dependent on DNA synthesis. Moreover, it is unlikely that scAAV genomes interact 
with the same cellular DDR pathway as ssAAV and this may lead to a different 
chromatin molecular signature on their DNA (Cataldi and McCarty, 2010). In this 
respect, ChIP experiments showed higher association of H3.3 histone variant, a 
marker of open chromatin, with scAAV than ssAAV. It is known that H3.3 can be 
loaded onto DNA in a replication-independent manner (Chow et al., 2005) and that 
it constitutes the predominant form of histone H3 in non-dividing cells (Wunsch 
and Lough, 1987) (Pina and Suau, 1987). Interestingly, previous reports have 
described histone H3.3 associated also with the double stranded DNA of helper 
dependent Adenovirus (Ross et al., 2011).  
While the H3.3 variant is prevalent on scAAV genomes, we observed that the H3 
canonical H3 form also immunoprecipitated with viral DNA (Figure 4.1). This 
finding is not surprising, since histone H3 can be loaded onto the double stranded 
AAV genome following intra-molecular and intermolecular recombination events 
that involve cellular DNA polymerases and topoisomerases (Choi et al., 2005) and 
CAF-1 as histone chaperone. Nevertheless, upon CAF-1 depletion, the ssAAV 
transgene expression increases two fold relative to scAAV infection, indicating that 
the siRNA against CAF-1 differentially increases ssAAV with respect to scAAV 
transduction.  
Changes in cellular histone dosage, mediated by Eri1, influence chromatin 
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assembly and composition on rAAV genomes. Han and Grunstein showed that 
nucleosome loss, through histone depletion, resulted in the increased 
transcription of numerous genes in yeast (Kim et al., 1988) and this provided the 
first in vivo evidence that nucleosomes can repress gene activity. Partial histone 
depletion can lead to an increase of homologous recombination and defects in 
DNA repair in eukaryotic cells (Prado and Aguilera, 2005). Consistent with the 
proposed model, we observed, by ChIP experiments, that the overexpression of 
Eri1 determined over 10-fold selective reduction of H3 and H4 histones associated 
with ssAAV genome paralleled by increased loading of the variant H3.3, while, in 
similar conditions, changes in histone composition were negligible for scAAV DNA. 
Conceivably, this double-stranded genome, immediately ready for transcription, 
presents an "open chromatin pattern", independent from CAF-1-mediated 
nucleosome assembly 
Collectively, these results indicate that Eri1 is an essential factor mediating cell 
permissivity to ssAAV transduction by relieving the inhibition that 
chromatinization and cellular DDR proteins impose on the incoming viral 
genomes.  This information can be exploited for the development of more 
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Figure 4.1 A model to explain cellular permissivity to ssAAV and scAAV. 
ssAAV is recognized by the host cell as damaged DNA. This event generates a repressive chromatin 
environment on ssAAV during the conversion to dsDNA, which is mediated by CAF-1. scAAV 
presents an "open chromatin pattern" as defined by its interaction with the histone H3.3 variant. 
Both hydroxyurea treatment and Eri1 overexpression lead to histone depletion by degrading 
histone mRNAs, thus causing chromatin relaxation. These results indicate AAV chromatinization is 
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HeLa, HEK293T, T98G, U2OS were purchased from the American Type Culture 
Collection (ATCC); MRC5 and AT5 cells were obtained in 2001 from F. d’Adda di 
Fagagna (The Wellcome/CRC Institute, Cambridge, United Kingdom). Huh7 cells 
were kindly  obtained from Alessandro Marcello ( ICGEB of Trieste). 
The cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% fetal bovine serum (Life Technologies) and antibiotics, in 






HeLa cells were plated in 96 multi-well plates at a final concentration of 1x104 cells 
per well. After 24 hours, cells were transfected with 50 ng of each DNA 
oligonucleotide used in this study, mixed with 0.12 μl Fugene lipofectamine 
(Promega) according to the manufacturer's recommendations. To obtain double-
stranded oligonugleotides, an equal volume of both complementary oligo 
sequences was mixed at equimolar concentration in a 1.5 ml microfuge tube, 
heated to 90–95 °C for 3–5 min and then slowly cooled down in about 45–60 min 
to room temperature. Oligonucleotides were purchased from Integrated DNA 
Technologies (IDT, Coralville, Iowa, USA). 
 
Sequences of used oligonucleotides:  
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20 bp, ACGAAGTCGCGAGACTGACG. 
30 bp, CGTTTATCGCGAGCTGGTAGTACCGTAGAT. 










The plasmids that express Eri1 fused with the green fluorescent protein at its C-
terminus as well as the Eri1 mutants ΔSAP, 105, and 235 were kindly provided by Z. 
Dominski (University of University of North Carolina , Chapel Hill, NC). Eri1 mutant 
cDNAs were subcloned by PCR into two different mammalian expression plasmids: 
1) N-Terminal p-FLAG-CMV (Sigma-Aldrich ) (Cloning sites: NotI ,SalI) 
Forward primer : ATAAGAATGCGGCCGCAGAGGATCCACAGAGTAA. 
Reverse primer:  TGCGGTCGACTTATTACTTTCTAAAATGTGGCATT . 
2) p-EGFP N1 ( Clontech ) (Cloning sites: XhoI, PstI) 
Forward primer: CCGCTCGAGATGGAGGATCCACAGAGTAA. 
Reverse primer: AACTGCAGGCGACTTTCTAAAATGTGGCATT. 
Eri1 wild type cDNA was also subclonend into the XhoI and AgeI sites into the p-
DsRed N1 monomer vector (Clonthech) 
 
Production of rAAV stocks 
 
The rAAV vectors used in this study, AAV2-EGFP, AAV2-DsRED, AAV2-Luc and 
AAV2sc-EGFP were prepared by the AAV Vector Unit at the International Centre for 
Genetic Engineering and Biotechnology Trieste (http://www.icgeb.org/avu-core-
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facility.html), as described previously (Arsic et al., 2004) with a few modifications. 
Briefly, infectious recombinant AAV vector particles were generated in HEK293T 
cells culture in roller bottles by dual plasmid co-transfection procedure with pDG 
as packaging helper plasmid (kindly provided by J. A. Kleinschmidt, DKFZ, 
Germany). Viral stocks were obtained by PEG precipitation and CsCl2 gradient 
centrifugation (Ayuso et al. 2009). The physical titer of recombinant AAVs was 
determined by quantifying vector genomes (vg) packaged into viral particles, by 
real-time PCR against a standard curve of a plasmid containing the vector genome 
(Zentilin et al., 2001); values obtained were in the range of 1x1012 to 1x1013 vg per 
milliliter.  
All the plasmids containing the AAV backbone, with the inverted terminal repeats, 
were grown in XL-10 Gold E. coli strain (Stratagene-Agilent Technologies, Santa 





For the AAV transduction experiments with ssAAV2-DsRed or scAAV2-EGFP, cells 
were cells were grown on 96-well plates or on 4-well chamber slides (Lab.Tek). At 
the indicated time points after AAV infection, plasmid transfection, or chemical 
treatments, cells were washed twice with PBS and fixed with 2% 
paraformaldehyde (Sigma  in PBS for 15 min at room temperature. Cells were 
permeabilized with 0.1% Triton X-100 in PBS for 20 min followed by 100% acetone 
at –20°C for 20 sec and blocked with 2% BSA and 0.15% glycine in PBS.  Plates were 
incubated with the indicated primary antibody in blocking solution overnight at 
4°C. The following antibodies were used:  rabbit anti phospho-NBS1 p-Ser343 
NB100-92610 (Novus Biologicals CO, USA) (1:100), anti-phosoho-histone-H2A.X 
Ser139 05-636 (Merck Millipore MA, USA) (1:200). After washing, samples were 
stained with secondary anti-rabbit or anti-mouse IgG conjugated with Alexa-Flour 
488 or Alexa-Flour 594 (Molecular Probes, Eugene, OR, USA), dilution 1:1000, for 1 
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hour at room temperature. Samples were washed with PBS + 0.1% Tween and 
mounted in Vectashield Mounting Medium containing 4’-6’-diamino-2-
phenylidole (DAPI) (Vector Laboratories, Burlingame, CA, USA) or with Hoechst 
33258 (Life Technologies). 
Acquisition of images  from 96 multiwell plates was performed using 
ImagineXpress Micro automated high-content screening fluorescence microscope 
(Molecular Devices CA, USA) at 10X magnification; a total of 9 imagines were 
acquired per well, corresponding to approximately 10.000 -15.000 cells per 
condition. Imagine analysis was performed using the “Multi-Wavelenght Cell 






Cells were reverse-transfected in antibiotic-free 1g/l glucose 10% fetal bovine 
serum Dulbecco's modified eagle medium using Lipofectamine® RNAiMAX (Life 
technologies), according to the manufacturer's recommendations.  
Dharmacon SMART - pool® (four siRNAs per gene) against SETD8 (M-031917-00-
0005), CASP82AP2 (M-012413-01-0005), SOX15 (M-012354-00-0005), TROAP (M-
019980-01-0005), NPAT (M-019599-02-0005), PHC3 (M-015805-01-0005), SF3B1 (M-
020061-02-0005), CAF-1, RTBDN (M-014723-01-0005), BOMB (M-016585-01-0005), 
CORF146 (M-018430-00-0005), Eri1 (M-021497-01-0005), RDBP (M-011761-01-
0005), BCCIP (M-013030-01-0005), MSH5 (M-011337-01-0005), SCGB1D1 (M-
012290-00-0005), PIK4CA (M-006776-04-0005) were used at the final concentration 
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Western blotting 
 
Total cell lysates were prepared from cells treated with siRNAs. For the 
immunoblotting, the cells were scraped at 4°C in HNNG buffer (15 mM Hepes pH 
7.5, 250 mM NaCl, 1% NP-40, 5% glycerol, 1 mM PMSF) supplemented with 25 mM 
NaF, 10 mM β-glycerophosphate, 0.2 mM sodium orthovanadate and protease 
inhibitors cocktail tablet (Roche). The samples were heated to 90°C for 5 min 
before loading. Protein concentration was determined by the colorimetric BCA 
protein assay reading at 562 nm absorbance (Thermo Fisher Scientific, Madison, 
WI, USA) using atomatize Envision 2014 Multilabel Reader (PerkinElmer, Inc USA). 
Fifteen μg of proteins were resolved on 8% to 12% SDS-PAGE minigels, and 
transferred onto reinforced nitrocellulose membranes (Optitran BA-S 83, Whatman 
GE Healthcare, Life Sciences).  
Before immunoblotting with the primary antibodies for phospho-H2AX and 
phospho-ATM, membranes were blocked in 5% Bovine serum albumin (BSA) in 
TBST (50 mM Tris-HCl pH 7.4, 200 mM NaCl, 0.04 % Tween 20) at room temperature 
for 2 hours. Immunoblots with the primary antibody for p-NBS1 were blocked 
over-night in 5% non-fat dry milk; immunoblots with the primary antibodies for 
NBS1, P-Chk1, ATM, Chk1, α-tubulin and anti- HSP70 were blocked in 5% non-fat 
dry milk for two hours at room temperature for 2 hours.   
Primary antibodies detection was achieved with horseradish peroxidase-
conjugated anti-rabbit or anti-mouse secondary antibodies (Santa Cruz CA, USA 
Biotechnology), diluted 1:3000, and exposure to X-ray film (Kodak) after incubation 
with ECL chemiluminescence solution (ECL™ Prime, GE Healthcare Amersham™). 
The following antibodies were used in this study: mouse anti-α-tubulin and anti-
HSP70 (diluted 1:10,000 in 5% non-fat dry milk) (Sigma Aldrich), mouse anti-
Phospho-ATM p-Ser1981 (diluted 1: 500 in 5% BSA) mAb 4526 (Cell Signaling, MA, 
USA), rabbit anti-ATM total D2E2 (diluted 1:500 in 5% BSA) (Cell Signaling, MA, 
USA), rabbit anti phospho-NBS1 p-Ser343 (diluted 1:500 in 5% non-fat dry milk) 
NB100-92610 (Novus Biologicals CO, USA), rabbit NBS1 total (diluted 1:3000 in 
	   97 
non-fat dry milk) NB-100143 (Novus Biologicals CO, USA), rabbit p-Chk1 p-Ser345 
(diluted 1:500 in 5% BSA) 133D3 (Cell Signaling, MA, USA), mouse Chk1 total   
(diluted 1:1000 in non-fat dry milk) 2D1G5 (Cell Signaling, MA, USA), mouse anti-
phosoho-histone-H2A.X Ser139 (diluted 1:500 in 5% BSA) 05-636 (Merck Millipore 
MA, USA).  Hydroxyurea (HU, Sigma) was used a positive control in all these 
experiments; where indicated, cells were incubated overnight with 1 mM HU. 
 
 
Gene expression analysis 
 
Total RNA from tissues and cells was isolated using TRIzol solution (Invitrogen). 
Total RNA was  reverse transcribed using random primers (Invitrogen) and M-MLV 
reverse transcriptase (Invitrogen). Real-time quantitative PCR (qPCR) analysis was 
performed using the iQ™Supermix (BioRad) and TaqMan® Gene Expression Assays 
(Applied Biosystems) specific for the following transcripts of human origin: Eri1(# 
4351372), H2A.Z (# 4331182) HPRT (# 4331182), GAPDH (# 4331182).  
The amplification reactions were run in duplicates on the CFX96 Real-Time PCR 
Detection System/C1000 Thermal Cycler  (BioRad) for 40 cycles using universal 
cycling conditions (95°C for 10 min, followed by 40 cycles of 95°C for 15 sec and 
60°C for 1 min), according to the manufacturer's recommendations. Results were 
normalized to HPRT or GAPDH housekeeping genes.  
 
 
Chromatin immunoprecipitation (ChIP) 
 
Aproximatly 20x106 HEK293T cells were co-transduced with self-complemetary 
AAV2-EGFP and single strand AAV2 DsRed at an moi of 104 vgp/cell each. Where 
indicated, cells were pre-treated with 1 mM HU overnight or transfected with an 
expression plasmid for Eri1 48 hours before infection. At 24 hours after infection, 
cells were washed with PBS and subsequently fixed by adding fixing solution (11% 
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formaldehyde, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA pH 8.0, 50 mM Tris-HCl pH 
8.0) directly to the aderent cells at 1% final concentration. Cross-linking reaction 
was allowed to proceed for 10 min at 37°C and was stopped by the addition of 
glycine at a final concentration of 0.125 M. Fixed cells were scraped and collected 
in 50 ml falcon tubes. The cells were washed once in ice-cold PBS, once in buffer B1 
(0.25% Triton X-100, 10 mM EDTA, 0.5 mM EGTA, 10 mM Tris-HCl pH 8.0) and once 
in buffer B2 (1 mM EDTA, 0.5 mM EGTA, 200 mM NaCl, 10 mM Tris-HCl pH 8.0, 4% 
NP-40). Cells were digested with 1.5 unit of MNase per 106 cells lysate (S7 nuclease, 
Roche Applied Science) for 15 min at 37°C and the reaction was stopped by adding 
EDTA, 3 mM final concentration. Cells were pelleted by centrifugation at 700 x g 
per xx min and resuspended in RIPA 50 buffer  
(50 mM NaCl, 20 mM Tris-HCl pH 7.4, 1 mM EDTA, 0.5% NP-40, 0.5% deoxycholic 
acid, 0.1% sodium dodecyl sulfate (SDS), protease inhibitors). Chromatin was 
sonicated (45 pulses, 10 sec on and 10 sec stop) on ice and centrifuged to pellet 
debris. Immunoprecipitations were precleared by adding 100 μl of total Protein 
A/G PLUS-Agarose (Santa Cruz CA, USA) for 3 hours at 4°.  
Tree μg of primary antibody per mg of total protein was used (an average 2-5 μl of 
pure antibody per lysate deriving from 5x106 cells, depending on the antibody 
concentration). The primary antibody was incubated at 4°C overnight. Immune 
complexes were collected with 100 μl of protein A/G PLUS-Agarose (Santa Cruz CA, 
USA), and beads were washed two times with RIPA 150 buffer (same as RIPA 50 but 
with 150 mM NaCl), two times with low-salt-wash-buffer (0.1% SDS 0.1% Triton X-
100 500 mM NaCl 2mM EDTA 20mM Tris-HCl pH 8.0), two times with high-salt-
wash-buffer (1mM EDTA, 10mM Tris-HCl pH 8.0, 1% NP-40, 1% DOC, 0.25M LiCl). 
Protein-DNA complexes were washed once in TE buffer and finally resuspended in 
200 μl of TE buffer and digested with 5 IU of DNase-free RNase (Roche) for 30 min 
at 37°C. Samples were then treated for 3 hours at 56°C with 300 g/ml proteinase K 
(Sigma) in 0.5% SDS, 100 mM NaCl, and were incubated overnight at 65°C to revert 
crosslinks. DNA was extracted with phenol-chloroform-isoamyl alcohol, ethanol 
precipitation and resuspended in water for real-time PCR quantification of scAAV 
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and dsRed AAV genome.  Quantitative SYBR green PCR was performed using 
primer pairs that bind both ssAAV and scAAV genome under the following 
condition : Activation at 95°C for 2 min, 40 cycles of denaturation at 95°C for 3 sec 
and annealing/extension at 60°C for 30 sec, followed by melting analysis ramping 
at 60°C to 95°C. 
Primer pairs used :  
GFP forward : 5’- CAGAAGAACGGCATCAAGGT - 3’ 
GFP Reverse : 5’ - ACTGGGTGCTCAGGTAGTGG - 3’ 
DsRed forward : 5’ - TCCATGAACTTCGAGGACGG - 3’ 
DeRed Reverse : 5’ - GCCCTTGAACTTCACCTTGTAG - 3’ 
 
The following antibodies were used for chromatin immunoprecipitation: anti-
histone H3 total, (06-755) (Merck Millipore MA, USA), anti-histone H4 total (07-108) 
(Merck Millipore MA, USA), anti-histone H3.3 (09-838) (Merck Millipore MA, USA), 
anti-trimethyl-histone H3 (Lys9) (05-1242), Anti-acetyl-Histone H3 Antibody 06-599 
(Merck Millipore MA, USA), anti-CAF-1 (04-1523) (Merck Millipore MA, USA), anti-
NBS1 (NB-100143) (Novus Biologicals CO, USA), anti-histone H2AX (07-627) (Merck 






Unless otherwise indicated, all data are presented as mean ± standard error of the 
mean (s.e.m.). Statistical analysis was carried out using Prism Software (GraphPad). 
For statistical comparison of two groups, two-tailed Student’s t-test was used. 
Analysis of multiple data sets was performed using one-way ANOVA followed by 
Tukeys post-hoc test. Star code for significance: *** P< 0.001, ** 0.001<P<0.01, ** 
0.01<P<0.05, n.s. not significant. 
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